<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Brain</journal-id>
      <journal-id journal-id-type="iso-abbrev">Brain</journal-id>
      <journal-id journal-id-type="publisher-id">brainj</journal-id>
      <journal-title-group>
        <journal-title>Brain</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0006-8950</issn>
      <issn pub-type="epub">1460-2156</issn>
      <publisher>
        <publisher-name>Oxford University Press</publisher-name>
        <publisher-loc>US</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">36073231</article-id>
      <article-id pub-id-type="pmc">10115167</article-id>
      <article-id pub-id-type="doi">10.1093/brain/awac326</article-id>
      <article-id pub-id-type="publisher-id">awac326</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
        <subj-group subj-group-type="category-taxonomy-collection">
          <subject>AcademicSubjects/MED00310</subject>
          <subject>AcademicSubjects/SCI01870</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>
<italic toggle="yes">PTPA</italic> variants and impaired PP2A activity in early-onset parkinsonism with intellectual disability</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8267-564X</contrib-id>
          <name>
            <surname>Fevga</surname>
            <given-names>Christina</given-names>
          </name>
          <aff>
<institution>Department of Clinical Genetics, Erasmus University Medical Center Rotterdam, Erasmus MC</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff>
          <xref rid="awac326-FM1" ref-type="author-notes"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tesson</surname>
            <given-names>Christelle</given-names>
          </name>
          <aff>
<institution>Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Sorbonne Universit&#xE9;</institution>, <addr-line>Paris</addr-line>, <country country="FR">France</country></aff>
          <xref rid="awac326-FM1" ref-type="author-notes"/>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8962-755X</contrib-id>
          <name>
            <surname>Carreras Mascaro</surname>
            <given-names>Ana</given-names>
          </name>
          <aff>
<institution>Department of Clinical Genetics, Erasmus University Medical Center Rotterdam, Erasmus MC</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff>
          <xref rid="awac326-FM1" ref-type="author-notes"/>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0275-2498</contrib-id>
          <name>
            <surname>Courtin</surname>
            <given-names>Thomas</given-names>
          </name>
          <aff>
<institution>Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Sorbonne Universit&#xE9;</institution>, <addr-line>Paris</addr-line>, <country country="FR">France</country></aff>
          <aff>
<institution>Assistance Publique H&#xF4;pitaux de Paris, H&#xF4;pital Piti&#xE9;-Salp&#xEA;tri&#xE8;re, D&#xE9;partement de G&#xE9;n&#xE9;tique, DMU BioGeM</institution>, <addr-line>Paris</addr-line>, <country country="FR">France</country></aff>
          <xref rid="awac326-FM1" ref-type="author-notes"/>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6250-363X</contrib-id>
          <name>
            <surname>van Coller</surname>
            <given-names>Riaan</given-names>
          </name>
          <aff>
<institution>Department of Neurology, Faculty of Health Sciences, University of Pretoria</institution>, <addr-line>Pretoria</addr-line>, <country country="ZA">South Africa</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sakka</surname>
            <given-names>Salma</given-names>
          </name>
          <aff>
<institution>Research Unit in Neurogenetics, Clinical Investigation Center (CIC) at the CHU Habib Bourguiba</institution>, <addr-line>Sfax</addr-line>, <country country="TN">Tunisia</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1365-2529</contrib-id>
          <name>
            <surname>Ferraro</surname>
            <given-names>Federico</given-names>
          </name>
          <aff>
<institution>Department of Clinical Genetics, Erasmus University Medical Center Rotterdam, Erasmus MC</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Farhat</surname>
            <given-names>Nouha</given-names>
          </name>
          <aff>
<institution>Research Unit in Neurogenetics, Clinical Investigation Center (CIC) at the CHU Habib Bourguiba</institution>, <addr-line>Sfax</addr-line>, <country country="TN">Tunisia</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3508-3438</contrib-id>
          <name>
            <surname>Bardien</surname>
            <given-names>Soraya</given-names>
          </name>
          <aff>
<institution>Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University</institution>, <addr-line>Cape Town</addr-line>, <country country="ZA">South Africa</country></aff>
          <aff>
<institution>South African Medical Research Council/Stellenbosch University Genomics of Brain Disorders Research Unit, Stellenbosch University</institution>, <addr-line>Cape Town</addr-line>, <country country="ZA">South Africa</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6868-2154</contrib-id>
          <name>
            <surname>Damak</surname>
            <given-names>Mariem</given-names>
          </name>
          <aff>
<institution>Research Unit in Neurogenetics, Clinical Investigation Center (CIC) at the CHU Habib Bourguiba</institution>, <addr-line>Sfax</addr-line>, <country country="TN">Tunisia</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7677-426X</contrib-id>
          <name>
            <surname>Carr</surname>
            <given-names>Jonathan</given-names>
          </name>
          <aff>
<institution>Division of Neurology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University</institution>, <addr-line>Cape Town</addr-line>, <country country="ZA">South Africa</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ferrien</surname>
            <given-names>M&#xE9;lanie</given-names>
          </name>
          <aff>
<institution>Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Sorbonne Universit&#xE9;</institution>, <addr-line>Paris</addr-line>, <country country="FR">France</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Boumeester</surname>
            <given-names>Valerie</given-names>
          </name>
          <aff>
<institution>Department of Clinical Genetics, Erasmus University Medical Center Rotterdam, Erasmus MC</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hundscheid</surname>
            <given-names>Jasmijn</given-names>
          </name>
          <aff>
<institution>Department of Clinical Genetics, Erasmus University Medical Center Rotterdam, Erasmus MC</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Grillenzoni</surname>
            <given-names>Nicola</given-names>
          </name>
          <aff>
<institution>Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Sorbonne Universit&#xE9;</institution>, <addr-line>Paris</addr-line>, <country country="FR">France</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9061-7335</contrib-id>
          <name>
            <surname>Kessissoglou</surname>
            <given-names>Irini A</given-names>
          </name>
          <aff>
<institution>Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Sorbonne Universit&#xE9;</institution>, <addr-line>Paris</addr-line>, <country country="FR">France</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6242-6651</contrib-id>
          <name>
            <surname>Kuipers</surname>
            <given-names>Demy J S</given-names>
          </name>
          <aff>
<institution>Department of Clinical Genetics, Erasmus University Medical Center Rotterdam, Erasmus MC</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Quadri</surname>
            <given-names>Marialuisa</given-names>
          </name>
          <aff>
<institution>Department of Clinical Genetics, Erasmus University Medical Center Rotterdam, Erasmus MC</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <collab>French and Mediterranean Parkinson disease Genetics Study Group
<contrib-group><contrib contrib-type="author"><name><surname>Agid</surname><given-names>Yves</given-names></name></contrib><contrib contrib-type="author"><name><surname>Anheim</surname><given-names>Mathieu</given-names></name></contrib><contrib contrib-type="author"><name><surname>Borg</surname><given-names>Michel</given-names></name></contrib><contrib contrib-type="author"><name><surname>Brice</surname><given-names>Alexis</given-names></name></contrib><contrib contrib-type="author"><name><surname>Broussolle</surname><given-names>Emmanuel</given-names></name></contrib><contrib contrib-type="author"><name><surname>Corvol</surname><given-names>Jean-Christophe</given-names></name></contrib><contrib contrib-type="author"><name><surname>Damier</surname><given-names>Philippe</given-names></name></contrib><contrib contrib-type="author"><name><surname>Defebvre</surname><given-names>Luc</given-names></name></contrib><contrib contrib-type="author"><name><surname>D&#xFC;rr</surname><given-names>Alexandra</given-names></name></contrib><contrib contrib-type="author"><name><surname>Durif</surname><given-names>Franck</given-names></name></contrib><contrib contrib-type="author"><name><surname>Houeto</surname><given-names>Jean Luc</given-names></name></contrib><contrib contrib-type="author"><name><surname>Krack</surname><given-names>Paul</given-names></name></contrib><contrib contrib-type="author"><name><surname>Klebe</surname><given-names>Stephan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lesage</surname><given-names>Suzanne</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lohmann</surname><given-names>Ebba</given-names></name></contrib><contrib contrib-type="author"><name><surname>Martinez</surname><given-names>Maria</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mangone</surname><given-names>Graziella</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mariani</surname><given-names>Louise-Laure</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pollak</surname><given-names>Pierre</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rascol</surname><given-names>Olivier</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tison</surname><given-names>Fran&#xE7;ois</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tranchant</surname><given-names>Christine</given-names></name></contrib><contrib contrib-type="author"><name><surname>V&#xE9;rin</surname><given-names>Marc</given-names></name></contrib><contrib contrib-type="author"><name><surname>Viallet</surname><given-names>Fran&#xE7;ois</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vidailhet</surname><given-names>Marie</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lohmann</surname><given-names>Ebba</given-names></name></contrib><contrib contrib-type="author"><name><surname>Emre</surname><given-names>Murat</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hanagasi</surname><given-names>Hasmet</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bilgic</surname><given-names>Basar</given-names></name></contrib><contrib contrib-type="author"><name><surname>lu</surname><given-names>Bedia Marangozog</given-names></name></contrib><contrib contrib-type="author"><name><surname>Benmahdjoub</surname><given-names>Mustapha</given-names></name></contrib><contrib contrib-type="author"><name><surname>Arezki</surname><given-names>Mohammed</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bouchetara</surname><given-names>Sofiane A</given-names></name></contrib><contrib contrib-type="author"><name><surname>Benhassine</surname><given-names>Traki</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tazir</surname><given-names>Meriem</given-names></name></contrib><contrib contrib-type="author"><name><surname>Djebara</surname><given-names>Mouna Ben</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gouider</surname><given-names>Riadh</given-names></name></contrib><contrib contrib-type="author"><name><surname>Romdhan</surname><given-names>Sawssan Ben</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mhiri</surname><given-names>Chokri</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bouhouche</surname><given-names>Ahmed</given-names></name></contrib></contrib-group></collab>
        </contrib>
        <contrib contrib-type="author">
          <collab>International Parkinsonism Genetics Network
<contrib-group><contrib contrib-type="author"><name><surname>Bonifati</surname><given-names>Vincenzo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mandemakers</surname><given-names>Wim</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kievit</surname><given-names>Anneke J A</given-names></name></contrib><contrib contrib-type="author"><name><surname>Boon</surname><given-names>Agnita J W</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ferreira</surname><given-names>Joaquim J</given-names></name></contrib><contrib contrib-type="author"><name><surname>Guedes</surname><given-names>Leonor Correia</given-names></name></contrib><contrib contrib-type="author"><name><surname>Emre</surname><given-names>Murat</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hanagasi</surname><given-names>Hasmet A</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bilgic</surname><given-names>Basar</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tufekcioglu</surname><given-names>Zeynep</given-names></name></contrib><contrib contrib-type="author"><name><surname>Elibol</surname><given-names>Bulent</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dog.u</surname><given-names>Okan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gultekin</surname><given-names>Murat</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chien</surname><given-names>Hsin F</given-names></name></contrib><contrib contrib-type="author"><name><surname>Barbosa</surname><given-names>Egberto</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jardim</surname><given-names>Laura Bannach</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rieder</surname><given-names>Carlos R M</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Hsiu-Chen</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Chin-Song</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wu-Chou</surname><given-names>Yah-Huei</given-names></name></contrib><contrib contrib-type="author"><name><surname>Yeh</surname><given-names>Tu-Hsueh</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lopiano</surname><given-names>Leonardo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tassorelli</surname><given-names>Cristina</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pacchetti</surname><given-names>Claudio</given-names></name></contrib><contrib contrib-type="author"><name><surname>Comi</surname><given-names>Cristoforo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Raudino</surname><given-names>Francesco</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bertolasi</surname><given-names>Laura</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tinazzi</surname><given-names>Michele</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bonizzato</surname><given-names>Alberto</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ferracci</surname><given-names>Carlo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Marconi</surname><given-names>Roberto</given-names></name></contrib><contrib contrib-type="author"><name><surname>Guidi</surname><given-names>Marco</given-names></name></contrib><contrib contrib-type="author"><name><surname>Onofrj</surname><given-names>Marco</given-names></name></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>Astrid</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vanacore</surname><given-names>Nicola</given-names></name></contrib><contrib contrib-type="author"><name><surname>Meco</surname><given-names>Giuseppe</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fabrizio</surname><given-names>Edito</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fabbrini</surname><given-names>Giovanni</given-names></name></contrib><contrib contrib-type="author"><name><surname>Berardelli</surname><given-names>Alfredo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Stocchi</surname><given-names>Fabrizio</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vacca</surname><given-names>Laura</given-names></name></contrib><contrib contrib-type="author"><name><surname>Barone</surname><given-names>Paolo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Picillo</surname><given-names>Marina</given-names></name></contrib><contrib contrib-type="author"><name><surname>De Michele</surname><given-names>Giuseppe</given-names></name></contrib><contrib contrib-type="author"><name><surname>Criscuolo</surname><given-names>Chiara</given-names></name></contrib><contrib contrib-type="author"><name><surname>De Mari</surname><given-names>Michele</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dell&#x2019;Aquila</surname><given-names>Claudia</given-names></name></contrib><contrib contrib-type="author"><name><surname>Iliceto</surname><given-names>Giovanni</given-names></name></contrib><contrib contrib-type="author"><name><surname>Toni</surname><given-names>Vincenzo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Trianni</surname><given-names>Giorgio</given-names></name></contrib><contrib contrib-type="author"><name><surname>Saddi</surname><given-names>Valeria</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cossu</surname><given-names>Gianni</given-names></name></contrib><contrib contrib-type="author"><name><surname>Melis</surname><given-names>Maurizio</given-names></name></contrib></contrib-group></collab>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7325-0199</contrib-id>
          <name>
            <surname>Corvol</surname>
            <given-names>Jean-Christophe</given-names>
          </name>
          <aff>
<institution>Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Sorbonne Universit&#xE9;</institution>, <addr-line>Paris</addr-line>, <country country="FR">France</country></aff>
          <aff>
<institution>Assistance Publique H&#xF4;pitaux de Paris, H&#xF4;pital Piti&#xE9;-Salp&#xEA;tri&#xE8;re, D&#xE9;partement de Neurologie, Centre d'Investigation Clinique Neurosciences, DMU Neuroscience</institution>, <addr-line>Paris</addr-line>, <country country="FR">France</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7591-6994</contrib-id>
          <name>
            <surname>Mhiri</surname>
            <given-names>Chokri</given-names>
          </name>
          <aff>
<institution>Research Unit in Neurogenetics, Clinical Investigation Center (CIC) at the CHU Habib Bourguiba</institution>, <addr-line>Sfax</addr-line>, <country country="TN">Tunisia</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9533-4908</contrib-id>
          <name>
            <surname>Hassan</surname>
            <given-names>Bassem A</given-names>
          </name>
          <aff>
<institution>Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Sorbonne Universit&#xE9;</institution>, <addr-line>Paris</addr-line>, <country country="FR">France</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4392-5906</contrib-id>
          <name>
            <surname>Breedveld</surname>
            <given-names>Guido J</given-names>
          </name>
          <aff>
<institution>Department of Clinical Genetics, Erasmus University Medical Center Rotterdam, Erasmus MC</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lesage</surname>
            <given-names>Suzanne</given-names>
          </name>
          <aff>
<institution>Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Sorbonne Universit&#xE9;</institution>, <addr-line>Paris</addr-line>, <country country="FR">France</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2673-5972</contrib-id>
          <name>
            <surname>Mandemakers</surname>
            <given-names>Wim</given-names>
          </name>
          <aff>
<institution>Department of Clinical Genetics, Erasmus University Medical Center Rotterdam, Erasmus MC</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0941-3990</contrib-id>
          <name>
            <surname>Brice</surname>
            <given-names>Alexis</given-names>
          </name>
          <aff>
<institution>Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Sorbonne Universit&#xE9;</institution>, <addr-line>Paris</addr-line>, <country country="FR">France</country></aff>
          <aff>
<institution>Assistance Publique H&#xF4;pitaux de Paris, H&#xF4;pital Piti&#xE9;-Salp&#xEA;tri&#xE8;re, D&#xE9;partement de G&#xE9;n&#xE9;tique, DMU BioGeM</institution>, <addr-line>Paris</addr-line>, <country country="FR">France</country></aff>
          <xref rid="awac326-FM1" ref-type="author-notes"/>
          <xref rid="awac326-cor1" ref-type="corresp"/>
          <!--alexis.brice@icm-institute.org-->
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9334-1263</contrib-id>
          <name>
            <surname>Bonifati</surname>
            <given-names>Vincenzo</given-names>
          </name>
          <aff>
<institution>Department of Clinical Genetics, Erasmus University Medical Center Rotterdam, Erasmus MC</institution>, <addr-line>3015 GD Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff>
          <xref rid="awac326-FM1" ref-type="author-notes"/>
          <xref rid="awac326-cor2" ref-type="corresp"/>
          <!--v.bonifati@erasmusmc.nl-->
        </contrib>
      </contrib-group>
      <author-notes>
        <fn id="awac326-FM1">
          <p>Christina Fevga, Christelle Tesson, Ana Carreras Mascaro, Thomas Courtin, Alexis Brice and Vincenzo Bonifati contributed equally to this work.</p>
        </fn>
        <corresp id="awac326-cor1">Correspondence to: Dr Alexis Brice Institut du Cerveau, H&#xF4;pital Piti&#xE9;-Salp&#xEA;tri&#xE8;re 47 bd de l&#x2019;H&#xF4;pital, 75013 Paris, France E-mail: <email>alexis.brice@icm-institute.org</email></corresp>
        <corresp id="awac326-cor2">Correspondence to: Dr Vincenzo Bonifati Department of Clinical Genetics, Erasmus MC PO Box 2040, 3000 CA Rotterdam, The Netherlands E-mail: <email>v.bonifati@erasmusmc.nl</email></corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <month>4</month>
        <year>2023</year>
      </pub-date>
      <pub-date pub-type="epub" iso-8601-date="2022-09-08">
        <day>08</day>
        <month>9</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>08</day>
        <month>9</month>
        <year>2022</year>
      </pub-date>
      <volume>146</volume>
      <issue>4</issue>
      <fpage>1496</fpage>
      <lpage>1510</lpage>
      <history>
        <date date-type="received">
          <day>29</day>
          <month>3</month>
          <year>2022</year>
        </date>
        <date date-type="rev-recd">
          <day>24</day>
          <month>6</month>
          <year>2022</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>8</month>
          <year>2022</year>
        </date>
        <date date-type="corrected-typeset">
          <day>24</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.</copyright-statement>
        <copyright-year>2022</copyright-year>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="awac326.pdf"/>
      <abstract>
        <title>Abstract</title>
        <p>The protein phosphatase 2A complex (PP2A), the major Ser/Thr phosphatase in the brain, is involved in a number of signalling pathways and functions, including the regulation of crucial proteins for neurodegeneration, such as alpha-synuclein, tau and LRRK2. Here, we report the identification of variants in the <italic toggle="yes">PTPA</italic>/<italic toggle="yes">PPP2R4</italic> gene, encoding a major PP2A activator, in two families with early-onset parkinsonism and intellectual disability.</p>
        <p>We carried out clinical studies and genetic analyses, including genome-wide linkage analysis, whole-exome sequencing, and Sanger sequencing of candidate variants. We next performed functional studies on the disease-associated variants in cultured cells and knock-down of <italic toggle="yes">ptpa</italic> in <italic toggle="yes">Drosophila melanogaster</italic>.</p>
        <p>We first identified a homozygous <italic toggle="yes">PTPA</italic> variant, c.893T&gt;G (p.Met298Arg), in patients from a South African family with early-onset parkinsonism and intellectual disability. Screening of a large series of additional families yielded a second homozygous variant, c.512C&gt;A (p.Ala171Asp), in a Libyan family with a similar phenotype. Both variants co-segregate with disease in the respective families. The affected subjects display juvenile-onset parkinsonism and intellectual disability. The motor symptoms were responsive to treatment with levodopa and deep brain stimulation of the subthalamic nucleus.</p>
        <p>In overexpression studies, both the PTPA p.Ala171Asp and p.Met298Arg variants were associated with decreased <italic toggle="yes">PTPA</italic> RNA stability and decreased PTPA protein levels; the p.Ala171Asp variant additionally displayed decreased PTPA protein stability. Crucially, expression of both variants was associated with decreased PP2A complex levels and impaired PP2A phosphatase activation. <italic toggle="yes">PTPA</italic> orthologue knock-down in <italic toggle="yes">Drosophila</italic> neurons induced a significant impairment of locomotion in the climbing test. This defect was age-dependent and fully reversed by L-DOPA treatment.</p>
        <p>We conclude that bi-allelic missense <italic toggle="yes">PTPA</italic> variants associated with impaired activation of the PP2A phosphatase cause autosomal recessive early-onset parkinsonism with intellectual disability. Our findings might also provide new insights for understanding the role of the PP2A complex in the pathogenesis of more common forms of neurodegeneration.</p>
      </abstract>
      <abstract abstract-type="teaser">
        <p>Fevga, Tesson, Carreras Mascaro, Courtin <italic toggle="yes">et al.</italic> identify homozygous <italic toggle="yes">PTPA</italic> variants co-segregating with parkinsonism and intellectual disability in two families. Both variants are associated with reduced PTPA levels and impaired activation of PP2A <italic toggle="yes">in vitro</italic>. <italic toggle="yes">PTPA</italic> knockdown in <italic toggle="yes">Drosophila</italic> induces levodopa-sensitive motor impairment.</p>
      </abstract>
      <kwd-group>
        <kwd>PTPA</kwd>
        <kwd>PPP2R4</kwd>
        <kwd>parkinsonism</kwd>
        <kwd>intellectual disability</kwd>
        <kwd>PP2A</kwd>
      </kwd-group>
      <funding-group>
        <award-group award-type="grant">
          <funding-source>
<institution-wrap><institution>Stichting ParkinsonFonds</institution><institution-id institution-id-type="doi">10.13039/501100008383</institution-id></institution-wrap>
</funding-source>
        </award-group>
        <award-group award-type="grant">
          <funding-source>
<institution-wrap><institution>Fondation pour la Recherche M&#xE9;dicale</institution><institution-id institution-id-type="doi">10.13039/501100002915</institution-id></institution-wrap>
</funding-source>
        </award-group>
        <award-group award-type="grant">
          <funding-source>
<institution-wrap><institution>Fondation de France</institution><institution-id institution-id-type="doi">10.13039/501100004431</institution-id></institution-wrap>
</funding-source>
        </award-group>
        <award-group award-type="grant">
          <funding-source>
<institution-wrap><institution>France-Parkinson Association</institution></institution-wrap>
</funding-source>
        </award-group>
        <award-group award-type="grant">
          <funding-source>
<institution-wrap><institution>F&#xE9;d&#xE9;ration pour la Recherche sur le Cerveau</institution><institution-id institution-id-type="doi">10.13039/501100006424</institution-id></institution-wrap>
</funding-source>
        </award-group>
        <award-group award-type="grant">
          <funding-source>
<institution-wrap><institution>South African Medical Research Council</institution><institution-id institution-id-type="doi">10.13039/501100001322</institution-id></institution-wrap>
</funding-source>
        </award-group>
        <award-group award-type="grant">
          <funding-source>
<institution-wrap><institution>National Research Foundation of South Africa</institution></institution-wrap>
</funding-source>
        </award-group>
      </funding-group>
      <counts>
        <page-count count="15"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="awac326-s0">
      <title>Introduction</title>
      <p>The identification of monogenic forms of Parkinson&#x2019;s disease (PD) and parkinsonism has shed light on molecular pathways underlying the disease pathogenesis and pointed to new therapeutic targets. Rare heterozygous variants in <italic toggle="yes">SNCA</italic>,<sup><xref rid="awac326-B1" ref-type="bibr">1</xref></sup><italic toggle="yes">LRRK2</italic>,<sup><xref rid="awac326-B2" ref-type="bibr">2</xref>,<xref rid="awac326-B3" ref-type="bibr">3</xref></sup> and <italic toggle="yes">VPS35</italic><sup><xref rid="awac326-B4" ref-type="bibr">4</xref>,<xref rid="awac326-B5" ref-type="bibr">5</xref></sup> are established causes of autosomal dominant forms of typical PD, while bi-allelic variants in <italic toggle="yes">PRKN</italic>,<sup><xref rid="awac326-B6" ref-type="bibr">6</xref></sup><italic toggle="yes">PINK1</italic>,<sup><xref rid="awac326-B7" ref-type="bibr">7</xref></sup> and <italic toggle="yes">DJ-1</italic><sup><xref rid="awac326-B8" ref-type="bibr">8</xref></sup> cause autosomal recessive (AR) forms of PD, usually of early-onset. Furthermore, disease-causing variants in several other genes have been shown to cause atypical forms of juvenile parkinsonism, with variable occurrence of additional clinical features. Yet, other causative genes likely remain to be identified, as in many families, particularly with early-onset parkinsonism, variants are not detected in any established/nominated gene.</p>
      <p>In this study, we nominate <italic toggle="yes">PTPA</italic>/<italic toggle="yes">PPP2R4</italic> as a novel gene for early-onset parkinsonism and intellectual disability (ID). The encoded PP2A Phosphatase Activator (PTPA) is a major modulator of the protein phosphatase 2A (PP2A) complex function, and it is ubiquitously expressed throughout the human organism and within the brain. PP2A is the major Ser/Thr phosphatase in the brain and targets a myriad of proteins involved in diverse cellular functions such as cellular metabolism,<sup><xref rid="awac326-B9" ref-type="bibr">9</xref></sup> cell cycle and proliferation,<sup><xref rid="awac326-B10" ref-type="bibr">10</xref></sup> embryonic development,<sup><xref rid="awac326-B11" ref-type="bibr">11</xref></sup> cytoskeleton dynamics,<sup><xref rid="awac326-B12" ref-type="bibr">12</xref></sup> and apoptosis.<sup><xref rid="awac326-B13" ref-type="bibr">13</xref></sup> The PP2A core dimer is composed of a catalytic (PP2A-C) and a scaffolding subunit (PP2A-A). This core dimer associates with one of more than a dozen regulatory subunits (PP2A-B) to form the PP2A heterotrimeric holoenzyme.<sup><xref rid="awac326-B14" ref-type="bibr">14</xref></sup> These alternative regulatory subunits confer substrate and (sub)cellular localization specificity to the enzyme.<sup><xref rid="awac326-B14" ref-type="bibr">14</xref></sup></p>
      <p>The activation of PP2A<sup><xref rid="awac326-B15" ref-type="bibr">15</xref>,<xref rid="awac326-B16" ref-type="bibr">16</xref></sup> is highly dependent on its methylation,<sup><xref rid="awac326-B17" ref-type="bibr">17&#x2013;20</xref></sup> which is negatively regulated by the PP2A-specific methylesterase, PME-1.<sup><xref rid="awac326-B17" ref-type="bibr">17</xref>,<xref rid="awac326-B18" ref-type="bibr">18</xref></sup> PTPA plays a key activating role by binding PME-1 and counteracting its negative influence on PP2A.<sup><xref rid="awac326-B19" ref-type="bibr">19</xref>,<xref rid="awac326-B20" ref-type="bibr">20</xref></sup> This key modulating role of PTPA on PP2A function has also been shown <italic toggle="yes">in vivo</italic>, where <italic toggle="yes">PTPA</italic> loss-of-function (LOF) was found to resemble a PP2A-deficient state.<sup><xref rid="awac326-B16" ref-type="bibr">16</xref></sup> Furthermore, <italic toggle="yes">PTPA</italic> deletion has been found to be lethal in fruit fly<sup><xref rid="awac326-B21" ref-type="bibr">21</xref></sup> and yeast,<sup><xref rid="awac326-B16" ref-type="bibr">16</xref>,<xref rid="awac326-B22" ref-type="bibr">22</xref>,<xref rid="awac326-B23" ref-type="bibr">23</xref></sup> further highlighting its essential role in PP2A regulation.</p>
      <p>PP2A dysregulation has been implicated in neurodegenerative disorders. The methylated, and therefore active, form of PP2A appears to be decreased in post-mortem brains from subjects with PD, Alzheimer&#x2019;s disease, dementia with Lewy bodies, and progressive supranuclear palsy, whereas the level of demethylated PP2A is increased.<sup><xref rid="awac326-B24" ref-type="bibr">24</xref></sup> Furthermore, PP2A is known to directly target and dephosphorylate alpha-synuclein,<sup><xref rid="awac326-B25" ref-type="bibr">25</xref></sup> tyrosine hydroxylase,<sup><xref rid="awac326-B26" ref-type="bibr">26</xref></sup> LRRK2,<sup><xref rid="awac326-B27" ref-type="bibr">27</xref></sup> and tau.<sup><xref rid="awac326-B28" ref-type="bibr">28</xref></sup> PP2A has been shown to dephosphorylate phospho-Ser129 alpha-synuclein, the aggregation-prone form of alpha-synuclein.<sup><xref rid="awac326-B25" ref-type="bibr">25</xref></sup> Moreover, enhanced PP2A activity has been demonstrated to reduce phosphorylation and subsequent activation of tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis.<sup><xref rid="awac326-B29" ref-type="bibr">29</xref>,<xref rid="awac326-B30" ref-type="bibr">30</xref></sup> Finally, downregulation of PP2A activity might promote tau pathology in Alzheimer&#x2019;s disease<sup><xref rid="awac326-B31" ref-type="bibr">31</xref>,<xref rid="awac326-B32" ref-type="bibr">32</xref></sup> as well as cognitive and electrophysiological impairments in transgenic mice.<sup><xref rid="awac326-B32" ref-type="bibr">32</xref></sup></p>
      <p>Interestingly, deregulation of PTPA activity has also been observed in Angelman syndrome, a neurodevelopmental disorder with severe ID due to <italic toggle="yes">UBE3A</italic> LOF, encoding an E3 ubiquitin ligase that ubiquitinates PTPA.<sup><xref rid="awac326-B33" ref-type="bibr">33</xref></sup> To our knowledge, however, variants in <italic toggle="yes">PTPA</italic> have not previously been described as a cause of monogenic human disease. Here, we report the identification of different bi-allelic variants in <italic toggle="yes">PTPA</italic>, associated with impaired activation of PP2A, in patients from two families with parkinsonism and ID.</p>
    </sec>
    <sec sec-type="materials|methods" id="awac326-s1">
      <title>Materials and methods</title>
      <sec id="awac326-s1.1">
        <title>Patients</title>
        <p>The study procedures were approved by the ethical authorities at the participating institutions, and written informed consent was obtained for each participant. Initially, a South African family with two siblings affected by juvenile-onset parkinsonism and ID (Family 1) was clinically characterized and genetically studied. Subsequently, two large independent series of unrelated cases with early-onset (onset &lt;40 years) and/or recessive PD/parkinsonism were studied in order to identify additional <italic toggle="yes">PTPA</italic> variants. In a first series of 200 patients (Erasmus MC Rotterdam and the International Parkinsonism Genetics Network), the entire coding region and exon&#x2013;intron boundaries of <italic toggle="yes">PTPA</italic> (NM_178001) were screened by Sanger sequencing (primers listed in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>). This series comprised 91 probands with familial PD or parkinsonism, compatible with AR inheritance (12 patients with early-onset), 78 patients with sporadic early-onset PD, and 31 patients with early-onset atypical parkinsonism (four with parkinsonism and ID).</p>
        <p>The second series assembled by the French and Mediterranean Parkinson&#x2019;s Disease Genetics Study group (FMPD cohort) consisted of 589 index PD patients with available whole-exome sequencing (WES) data. Most of these patients present with early-onset PD. In this study group, no variants of interest were identified in known genes causing or related to PD/parkinsonism (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 2</xref>).</p>
        <p>This cohort included 661 patients with PD, 258 females and 403 males, from 589 families. Four hundred and ninety-two were from Europe, 82 from North Africa, seven from South Africa, and 80 of unknown origin. Among them, 87 families with at least two affected siblings (<italic toggle="yes">n</italic> = 159 patients) were compatible with AR PD, including 13 families (<italic toggle="yes">n</italic> = 22 patients) with parental consanguinity. 502 patients were isolated cases, including 62 with consanguinity. This cohort included 41 patients with familial early-onset parkinsonism (30 families) and three patients with early-onset parkinsonism and ID. WES data were available for all index cases, 72 additional affected members and 50 unaffected relatives. The mean age at onset of motor signs was 38.7 years (range: 6&#x2013;80 years). Seventeen patients presented either MMSE &lt;24, intellectual impairment or cognitive decline. Information on cognitive status was not available for 78 patients.</p>
      </sec>
      <sec id="awac326-s1.2">
        <title>Genetic studies</title>
        <p>Regarding Family 1, genomic DNA was extracted from peripheral blood using standard protocols. High-density genome-wide genotyping in Subjects F1-I-1, F1-I-2, F1-II-1, and F1-II-2 (<xref rid="awac326-F1" ref-type="fig">Fig. 1A</xref>) was carried out with the Infinium<sup>&#xAE;</sup> CytoSNP-850K v1.1 kit (Illumina), and we performed linkage analysis to generate a list of genomic regions of interest, defined as regions with logarithm of odds (LOD) score &gt;0. Multipoint parametric linkage analysis was performed with MERLIN<sup><xref rid="awac326-B34" ref-type="bibr">34</xref></sup> assuming an AR mode of inheritance.</p>
        <fig position="float" id="awac326-F1" fig-type="figure">
          <label>Figure 1</label>
          <caption>
            <p>
<bold>Pedigrees and identified <italic toggle="yes">PTPA</italic> variants. A</bold> and <bold>B</bold> show the pedigrees of Families 1 and 2, respectively. Filled symbols indicate individuals affected by parkinsonism; unfilled symbols indicate unaffected individuals; arrows denote index cases. AAO = age at onset; ref/var = heterozygous genotype for the corresponding variant; var/var = homozygous variant genotype; ref/ref = wild-type (reference) genotype. (<bold>C</bold>) <italic toggle="yes">PTPA</italic> gene schematic representation, including relative positions of the variants identified in this study annotated according to NM_178001. (<bold>D</bold>) 3D molecular rendering of PTPA, with the relative positions of the variants and the ATP binding and PP2A-C binding sites.</p>
          </caption>
          <graphic xlink:href="awac326f1" position="float"/>
        </fig>
        <p>WES on Subject F1-II-2 was performed by using the Nextera Rapid Capture Exome v1.2 kit (Illumina) and HiSeq4000, paired-end 150-bp sequencing (Illumina). The reads were processed according to the GATK v3.7 guidelines,<sup><xref rid="awac326-B35" ref-type="bibr">35</xref></sup> and aligned to the human reference genome GRCh37/hg19 with the Burrows-Wheeler Aligner (BWA).<sup><xref rid="awac326-B36" ref-type="bibr">36</xref></sup> The variants were called with GATK HaplotypeCaller.<sup><xref rid="awac326-B35" ref-type="bibr">35</xref></sup> Finally, WES variants were filtered using Alissa Interpret v5.3 (Agilent Technologies).</p>
        <p>In the WES data of Subject F1-II-2, we first searched for variants in genes causing/related to PD/parkinsonism (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 3</xref>). We then searched for variants located within the regions of interest with LOD &gt;0 resulting from the AR linkage analysis model. Variants were filtered if they (i) had a minor allele frequency (MAF) &lt;0.1% in public population databases as well as in in-house reference datasets; (ii) were homozygous or double heterozygous; and (iii) had a coding effect or were located within &#xB1;5 bp from intron-exon boundaries and predicted to affect splicing by at least one out of four tools (ADA,<sup><xref rid="awac326-B37" ref-type="bibr">37</xref></sup> RF,<sup><xref rid="awac326-B37" ref-type="bibr">37</xref></sup> SpliceAI,<sup><xref rid="awac326-B38" ref-type="bibr">38</xref></sup> and SQUIRLS<sup><xref rid="awac326-B39" ref-type="bibr">39</xref></sup>). Predictions and scores across <italic toggle="yes">in silico</italic> algorithms were obtained via the Ensembl Variant Effect Predictor (VEP) v105.<sup><xref rid="awac326-B40" ref-type="bibr">40</xref></sup></p>
        <p>Furthermore, genome-wide copy number variant analysis was performed with Nexus Copy Number v10 (BioDiscovery), PennCNV,<sup><xref rid="awac326-B41" ref-type="bibr">41</xref></sup> and QuantiSNP.<sup><xref rid="awac326-B42" ref-type="bibr">42</xref></sup> Copy number variants were considered of interest if they fulfilled the following criteria: called by at least two out of the three above-listed analysis tools and (i) located in genes causing and/or related to PD/parkinsonism (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 3</xref>) or (ii) spanning coding genes located in the linkage regions of interest with LOD &gt;0, in bi-allelic state in both affected siblings.</p>
        <p>WES in the FMPD cohort was performed at the ICM IGenSeq core facility, Integragen service (Evry, France) or through the NIH facility. Exons were captured using the SureSelect Human All Exon Kits Version 2 Agilent, the Human All Exon V4 + UTRs&#x2014;70 Mb Agilent, the Human All Exon Agilent, the Roche V.3, Medexome or the Twist Refseq kit, followed by a massively parallel sequencing on the HiSEQ 2000, or the NextSeq500 or NovaSeq system (Illumina). The mean coverage was 104.6&#xD7; (range 51.1&#x2013;216.4&#xD7;) and 25-, 30-, 50-fold mean sequencing depth was achieved across 85.1% (range 79.5&#x2013;90.4%), 86% (range 58.4&#x2013;95.5%) and 80.9% (range 57.0&#x2013;97.3%) of targeted regions, respectively. Read alignment and variant calling were done using an in-house pipeline. Briefly, FastQC was used to check the quality of the reads and low-quality reads were removed using Trimmomatic. Sequencing data were then aligned to the human reference genome hg19 using the bwa suite<sup><xref rid="awac326-B36" ref-type="bibr">36</xref></sup> and variant calling was performed using GATK HaplotypeCaller<sup><xref rid="awac326-B35" ref-type="bibr">35</xref></sup> or Dragen (Illumina).</p>
        <p>Exomes were analysed using VaraFT software.<sup><xref rid="awac326-B43" ref-type="bibr">43</xref></sup> Since all known PD genes (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 2</xref>) had been previously excluded, we filtered all homozygous or double heterozygous variants in <italic toggle="yes">PTPA</italic> that possibly affected the cDNA or localized in the splice site region (&#x2212;8 + 11 bp from exon/intron junction) and with a MAF &lt; 1% in the gnomAD public database.<sup><xref rid="awac326-B44" ref-type="bibr">44</xref></sup></p>
        <p>To assess whether <italic toggle="yes">PTPA</italic> variants contribute to the risk of PD, exploratory analyses were also performed in the FMPD cohort and in publicly available PD variant databases (<xref rid="sup1" ref-type="supplementary-material">Supplementary material, Appendix 4</xref>).</p>
      </sec>
      <sec id="awac326-s2">
        <title>3D structural modelling of PTPA</title>
        <p>We generated a schematic representation of the 3D structure of PTPA, including positions of the variants identified in this study as well as positions of ATP binding and PP2A-C binding sites. Atomic coordinates for the PTPA protein were downloaded from Protein Data Bank with accession code 2G62,<sup><xref rid="awac326-B45" ref-type="bibr">45</xref></sup> corresponding to the canonical isoform NP_821067 (NM_178000). Functional domains were annotated according to Chao <italic toggle="yes">et al</italic>.<sup><xref rid="awac326-B46" ref-type="bibr">46</xref></sup> Pymol 2.4.1 (Schr&#xF6;dinger LLC) was used to generate the molecular rendering.</p>
      </sec>
      <sec id="awac326-s2.1">
        <title>Cloning</title>
        <p>All DNA constructs used for overexpression experiments were derived from the sequence-verified pCMV3-PTPA cDNA plasmid, which contains the canonical cDNA sequence of <italic toggle="yes">PTPA</italic> (NM_178000; Sino Biological, HG12287-UT).<sup><xref rid="awac326-B47" ref-type="bibr">47</xref></sup> Both variants c.893T&gt;G and c.512C&gt;A were introduced using the QuikChange Lightning site-directed mutagenesis kit (Agilent, 210518), as recommended by the manufacturer. The negative control plasmid was generated by depletion of the <italic toggle="yes">PTPA</italic> insert via restriction digestion (HindIII and NotI), blunt end generation and T4 ligation. All plasmids were verified by Sanger sequencing.</p>
      </sec>
      <sec id="awac326-s2.2">
        <title>Cell culture, chemicals and transfection</title>
        <p>HEK-293 cell lines were expanded in growth medium (DMEM, ThermoFisher, 10% FCS) at 37&#xB0;C/5% CO<sub>2</sub>. Prior to transfection, cells were seeded to a 40&#x2013;50% confluency in tissue culture plates. Transfections were performed using GeneJuice&#xAE; reagent (Sigma-Aldrich, 70967) according to manufacturer&#x2019;s specifications, and the samples were further processed 48 h after transfection. Cycloheximide (40 &#x3BC;g/ml, Merck, C7698-1G), MG-132 (20 &#xB5;M, Enzo, BML-PI102-0005), Bafilomycin A1 (200 nM, Enzo, BML-CM110-0100) and Torin 1 (200 nM, Invivogen, inh-tor1) were mixed with growth medium and placed on the cells for the indicated time points at 37&#xB0;C/5% CO<sub>2</sub> immediately prior to protein extraction.</p>
      </sec>
      <sec id="awac326-s2.3">
        <title>Protein extraction</title>
        <p>Cultured cells were washed with TBS and lysed with protein lysis buffer (100 mM NaCl, 1.0% IGEPAL<sup>&#xAE;</sup> CA-630, 50 mM Tris-Cl, pH 7.4) containing protease inhibitors Complete<sup>&#xAE;</sup> (Merck) and Pefabloc<sup>&#xAE;</sup> SC (Merck). Lysates were snap frozen, thawed on ice and cleared by centrifugation at 10 000<italic toggle="yes">g</italic> for 10 min at 4&#xB0;C.</p>
      </sec>
      <sec id="awac326-s2.4">
        <title>Western blotting</title>
        <p>Protein extracts were mixed with 4&#xD7; sample buffer (8% SDS, 20% v/v glycerol, 0.002% bromphenolblue, 62.5 mM Tris-Cl, pH 6.8) supplemented with 100 mM dithiothreitol (DTT) and incubated for 10 min at 95&#xB0;C. Proteins were separated on 4&#x2013;15% Criterion TGX precast gels (Bio-Rad) and transferred to nitrocellulose membranes using the Trans-Blot<sup>&#xAE;</sup> Turbo&#x2122; Transfer System (Bio-Rad). Membranes were blocked using 5% non-fat dry milk (Blotto, Santa Cruz Biotechnologies) in TBS, 0.1% v/v Tween&#xAE; 20 (Merck) for 30 min to 1 h at room temperature. Primary antibody incubations were performed overnight at 4&#xB0;C in blocking buffer. The following primary antibodies were used: rabbit anti-PTPA (Cell Signaling Technologies, 3330, 1:1000 dilution), mouse anti-PTPA (BioLegend, 824401, 1:1000 dilution), mouse anti-PP2A C (Sigma-Aldrich, 05-421, 1:1000 dilution), rabbit anti-LC3B (Novus, NB100-2220, 1:1000 dilution), rabbit anti-GADD34 (Proteintech, 10449-1-AP, 1:1000 dilution), mouse anti-vinculin (Santa Cruz Biotechnology, V284, 1:2000 dilution). After washing in TBS, 0.1% v/v Tween<sup>&#xAE;</sup> 20, blots were incubated for 1 h at room temperature with fluorescently conjugated Alexa Fluor Plus 800 donkey anti-mouse and 700 donkey anti-rabbit (both from ThermoFisher) secondary antibodies. After washing in TBS, 0.1% v/v Tween<sup>&#xAE;</sup> 20, blots were imaged and analysed using the Odyssey CLx imaging system (LI-COR Biosciences).</p>
      </sec>
      <sec id="awac326-s2.5">
        <title>RNA isolation, cDNA generation and RT-qPCR</title>
        <p>Total RNA from cultured cells was isolated using the RNeasy Mini Kit (Qiagen) according to manufacturer&#x2019;s specifications. Integrity and size distribution of total RNA was checked by agarose gel electrophoresis and quantified using a Denovix DS-11_FX spectrophotometer. cDNA synthesis was performed with the RevertAid First Strand Synthesis kit (ThermoFisher, K1622) using 1.5 &#xB5;g RNA as starting material. RT-qPCR primer sets for targeting PTPA and PP2A-C and reference assays were designed using Primer3 and are listed in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 4</xref>.<sup><xref rid="awac326-B48" ref-type="bibr">48</xref></sup> Amplifications were carried out in technical triplicates using 0.2 &#xB5;l of 10&#xD7; diluted cDNA, 100 nM primers, and 1&#xD7; TaykonTM No Rox SYBR MasterMix dTTP Blue (Eurogentec, UF-NSMT-B0701) in a final volume of 15 &#xB5;l. Cycle conditions were 3 min at 95&#xB0;C followed by 40 cycles of 10 s at 95&#xB0;C, and 1 min at 60&#xB0;C in a Bio-Rad CFX96 real-time PCR detection system. Data analysis was performed using Maestro CFX 2.2 software (Bio-Rad). Briefly, the normalized expression of each target gene was calculated using the &#x394;&#x394;Cq method.<sup><xref rid="awac326-B49" ref-type="bibr">49</xref></sup> Relative <italic toggle="yes">PTPA</italic> and <italic toggle="yes">PP2A-C</italic> mRNA levels were determined after normalization to the geometric mean of the housekeeping genes <italic toggle="yes">COPS5</italic> and <italic toggle="yes">CLK2</italic>.</p>
      </sec>
      <sec id="awac326-s2.6">
        <title>PP2A phosphatase activity assay</title>
        <p>Total protein concentration from transfected HEK-293 cells lysates was determined using the Pierce&#x2122; BCA protein assay kit (Thermo Fisher scientific). Protein lysates (100 &#xB5;g) were mixed with 40 &#xB5;l of protein A agarose slurry (Santa Cruz Biotechnology, sc-2001) and 2 &#xB5;l of anti-PP2A C subunit antibody (Sigma-Aldrich, 05-421) in a total of 500 &#xB5;l with pNPP Ser/Thr assay buffer (Sigma-Aldrich, 20-179), and incubated for 2 h at 4&#xB0;C with constant rotation. Next, beads were washed three times with TBS and once with pNPP Ser/Thr assay buffer. Subsequently, threonine phosphopeptide (Sigma-Aldrich, 12-219) was added to the washed beads and pNPP Ser/Thr assay buffer to a final concentration of 500 &#xB5;M as substrate for the enzymatic reaction, and it was incubated for 10 min at 30&#xB0;C in a shaking incubator. Twenty-five microlitres of the enzymatic reaction were mixed with 100 &#xB5;l of Malachite Green Phosphate Detection Solution (solution A and additive, Sigma-Aldrich, 20&#x2013;105 and 20&#x2013;104, respectively) in a Corning<sup>&#xAE;</sup> 96-well half-area microplate (Merck, CLS3695-25EA), and incubated for 10 min at room temperature. Absorbance was measured at a wavelength of 650 nm in a Varioskan microtitre plate reader (ThermoFisher) and compared with the Phosphate standard (Sigma-Aldrich, 20-103).</p>
      </sec>
      <sec id="awac326-s2.7">
        <title>
<italic toggle="yes">Drosophila</italic> studies</title>
        <p>RNA-interference (RNAi) was used for targeted knock-down of gene expression in conjunction with the Gal4/UAS system of cell-type-specific transgene expression. Transgenic RNAi flies were generated based on a previously published protocol.<sup><xref rid="awac326-B50" ref-type="bibr">50</xref></sup> Orthologues were identified based on &#x2018;DIOPT ortholog finder&#x2019;.<sup><xref rid="awac326-B51" ref-type="bibr">51</xref></sup> We considered <italic toggle="yes">ptpa</italic> (FBgn0016698), <italic toggle="yes">prkn (</italic>FBgn0041100) and <italic toggle="yes">nsmase</italic> (FBgn0035421) as fly orthologues of <italic toggle="yes">PTPA</italic>, <italic toggle="yes">PRKN</italic> and <italic toggle="yes">SMPD2</italic>, respectively. The transgenic flies were obtained from VDRC Stock Center. The RNAi lines <italic toggle="yes">ptpa</italic> (VDRC ID: 41912), <italic toggle="yes">prkn</italic> (VDRC ID: 47636), and <italic toggle="yes">nsmase</italic> (VDRC ID: 107062) were crossed with a nSyb-Gal4 strain to drive pan-neuronal expression of the RNAi. Flies were raised on a 12:12 light:dark schedule at 25&#xB0;C and 60% relative humidity. Adult flies of indicated genotypes were tested for behavioural analyses at Days 10, 20, and 35. L-DOPA (D9628, Sigma) was mixed directly into melted fly food at a final concentration of 1 mg/ml. We used <italic toggle="yes">prkn</italic> as a positive control based on previous studies.<sup><xref rid="awac326-B52" ref-type="bibr">52</xref></sup> Based on previous behavioural tests (data not shown), we used <italic toggle="yes">nsmase</italic> as a negative control. Locomotor activity was evaluated using the climbing test based on negative-geotaxis analysis. The experiment was performed in triplicates, each test including at least 15 flies. The test was performed on all lines five times at each time point after a 1-min rest. Only females were tested. Flies that did not reach the middle of the tube (5 cm) 10 s after stimulation were considered as presenting a locomotor impairment. Fly count was automatically performed by ImageJ.<sup><xref rid="awac326-B53" ref-type="bibr">53</xref></sup></p>
      </sec>
      <sec id="awac326-s2.8">
        <title>Statistical analysis</title>
        <p>Statistical analyses were performed using Prism 9 software (GraphPad). For <italic toggle="yes">in vitro</italic> experiments, one-way ANOVA and Dunnett&#x2019;s <italic toggle="yes">post hoc</italic> test were used for experiments in basal conditions and two-way ANOVA followed by Tukey&#x2019;s <italic toggle="yes">post hoc</italic> test were used in experiments including drug treatments. Significant <italic toggle="yes">P</italic>-values of &lt;0.05 or lower were reported. Data are presented as means &#xB1; standard deviations (SD) and represent results from three or four biological replicates.</p>
        <p>Regarding the <italic toggle="yes">Drosophila</italic> studies, statistical analyses were performed in R (R 4.1.2, native package). For comparison between two genotypes, the &#x3C7;<sup>2</sup> test was performed.</p>
      </sec>
      <sec sec-type="data-availability" id="awac326-s2.9">
        <title>Data availability</title>
        <p>The data that support the findings of this study are available from the corresponding authors, upon reasonable request.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="awac326-s3">
      <title>Results</title>
      <sec id="awac326-s3.1">
        <title>Clinical studies</title>
        <p>The clinical features of the patients with <italic toggle="yes">PTPA</italic> variants are summarized in <xref rid="awac326-T1" ref-type="table">Table 1</xref>, and more detailed case-reports and videotapes of Family 1 patients are available (<xref rid="sup1" ref-type="supplementary-material">Supplementary material, Appendix 3</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Videos 1 and 2</xref>). The patients in these two families presented with a very similar phenotype (<xref rid="awac326-T1" ref-type="table">Table 1</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary material, Appendix 3</xref>). In short, in Family 1 (<xref rid="awac326-F1" ref-type="fig">Fig. 1A</xref>) the two affected siblings, born to non-consanguineous parents of South African descent, manifested learning disability and were unable to attend mainstream school in childhood and early adolescence. Early childhood development and motor and communication milestones were delayed in one sibling (Subject F1-II-1) but were normal in the other (Subject F1-II-2). The first signs of parkinsonism manifested at age 11 in both siblings. Brain MRI studies were unremarkable. At the last clinical follow-up (at ages 33 and 24 years, respectively), both patients were still independent in all basic activities of daily life, in keeping with no referred decline in cognitive or language abilities over the years. On the contrary, parkinsonism was clearly progressive in both siblings, with marked positive response to levodopa along with early development of severe, disabling levodopa-induced dyskinesias. Therefore, deep brain stimulation of the subthalamic nucleus (STN-DBS) was carried out, which was effective in both siblings.</p>
        <table-wrap position="float" id="awac326-T1">
          <label>Table 1</label>
          <caption>
            <p>Clinical findings in patients with <italic toggle="yes">PTPA</italic> variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="center" span="1"/>
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="center" span="1"/>
              <col valign="top" align="center" span="1"/>
              <col valign="top" align="center" span="1"/>
              <col valign="top" align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1">Patient/sex</th>
                <th align="center" rowspan="1" colspan="1">PTPA variant</th>
                <th align="center" rowspan="1" colspan="1">AAO/AAE</th>
                <th align="center" rowspan="1" colspan="1">Parkinsonian signs at onset</th>
                <th align="center" rowspan="1" colspan="1">Other clinical features</th>
                <th align="center" rowspan="1" colspan="1">Levodopa response</th>
                <th align="center" rowspan="1" colspan="1">Levodopa-induced dyskinesia</th>
                <th align="center" rowspan="1" colspan="1">STN-DBS response</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">F1-II-1/male</td>
                <td rowspan="1" colspan="1">p.Met298Arg (homozygous)</td>
                <td rowspan="1" colspan="1">11/33</td>
                <td rowspan="1" colspan="1">Rest tremor of the right hand</td>
                <td rowspan="1" colspan="1">ID; impulse control disorder while on dopamine agonists; constipation; sialorrhea</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1">+</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">F1-II-2/female</td>
                <td rowspan="1" colspan="1">p.Met298Arg (homozygous)</td>
                <td rowspan="1" colspan="1">11/24</td>
                <td rowspan="1" colspan="1">Gait and upper limbs hypo-/bradykinesia</td>
                <td rowspan="1" colspan="1">ID; anxiety; depression; restless legs syndrome</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1">+</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">F2-IV-5/female</td>
                <td rowspan="1" colspan="1">p.Ala171Asp (homozygous)</td>
                <td rowspan="1" colspan="1">15/32</td>
                <td rowspan="1" colspan="1">Bradykinesia; rest tremor of the right hand; rigidity; gait difficulties</td>
                <td rowspan="1" colspan="1">ID</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1">NP</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">F2-IV-4/male</td>
                <td rowspan="1" colspan="1">p.Ala171Asp (homozygous)</td>
                <td rowspan="1" colspan="1">16/31</td>
                <td rowspan="1" colspan="1">Bradykinesia</td>
                <td rowspan="1" colspan="1">ID</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1">-</td>
                <td rowspan="1" colspan="1">NP</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="awac326-tblfn1">
              <p>- = absent; + = present; AAE = age at last examination; AAO = age at onset of parkinsonian symptomatology; NP = not performed.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>The two affected siblings in Family 2 with the <italic toggle="yes">PTPA</italic> p.Ala171Asp variant were born to healthy first-cousin parents originating from Libya. The index case Subject F2-IV-5 (<xref rid="awac326-F1" ref-type="fig">Fig. 1B</xref>), a 32-year-old female, had normal developmental milestones. However, she stopped attending school at age 8 years because of ID. She developed progressive slowness of movements at age 15 years. She noticed insidious appearance of a tremor of the right hand particularly at rest, associated with rigidity of the lower limbs, resulting in gait difficulties. Neurological examination at age 15 years revealed an akinetic-rigid parkinsonian syndrome. Good response to levodopa therapy was obtained initially (500 mg/day) without motor fluctuation. At age 30 years, dyskinesia appeared and persisted despite splitting the daily dose of levodopa into four administrations/day. No sensory, sleep or autonomic dysfunctions, or psychiatric disorders were reported. Neuropsychological evaluation, performed at age 30 years, demonstrated a moderate cognitive impairment [Mini-Mental State Examination (MMSE) = 21]. Brain MRI was normal. Her brother, Subject F2-IV-4 (<xref rid="awac326-F1" ref-type="fig">Fig. 1B</xref>), a 31-year-old male, had normal developmental milestones. He stopped attending school at age 7 years due to ID. Since age 16 years, he developed progressive slowness of voluntary movements. There was no evidence of sleep or autonomic dysfunctions or psychiatric disorders. Neurological examination at age 31 years showed an akinetic-rigid parkinsonian syndrome. The administration of levodopa (250 mg/day) induced a complete relief of motor symptoms without dyskinesias. Neuropsychological assessment revealed a moderate cognitive impairment (MMSE = 20). Brain and cervical spinal cord MRI were normal. Their 26-year-old first cousin (Individual F2-IV-1) (<xref rid="awac326-F1" ref-type="fig">Fig. 1B</xref>) was followed-up for walking difficulties since age 16 years, displaying progressively worsening symptoms and moderate cognitive impairment. No DNA was available from this patient. Other family members, including both unaffected parents and the 29-year-old unaffected sibling (Individual F2-IV-2), for whom DNA was collected, displayed no signs or symptoms of ID or parkinsonism.</p>
      </sec>
      <sec id="awac326-s3.2">
        <title>Genetic studies</title>
        <p>WES in one sibling from Family 1 (<xref rid="awac326-F1" ref-type="fig">Fig. 1A</xref>; Subject F1-II-2) reached an average coverage of 119&#xD7; of target regions. No variants of interest were identified in known genes causing/related to PD/parkinsonism (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 3</xref>). In this family, linkage analysis yielded 41 regions with LOD score &gt;0 (maximum LOD = 0.204) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 1</xref>). Filtering these regions for WES variants yielded a unique variant in homozygous state, the <italic toggle="yes">PTPA</italic> (NM_178001) c.893T&gt;G, p.Met298Arg, and five additional variants in two other genes (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 5</xref>). Sanger sequencing confirmed the homozygous <italic toggle="yes">PTPA</italic> variant in Subject F1-II-2 and co-segregation of this variant with disease in this family (<xref rid="awac326-F1" ref-type="fig">Fig. 1A</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 2</xref>). Co-segregation analysis excluded all the other variants identified under the AR inheritance model. In addition, we did not find any evidence of copy number variants shared by both affected siblings in this family. The <italic toggle="yes">PTPA</italic> variant is absent in population databases, predicted deleterious by most <italic toggle="yes">in silico</italic> algorithms [Combined Annotation Dependent Depletion score (CADD)<sup><xref rid="awac326-B54" ref-type="bibr">54</xref></sup> = 32; <xref rid="awac326-T2" ref-type="table">Table 2</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 6</xref>] and Met298 is highly conserved among orthologues (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 3</xref>). Taking into account the absence of other disease-co-segregating variants in the genomic regions of interest, the predicted pathogenicity of the <italic toggle="yes">PTPA</italic> variant, as well as the known functional links between the PP2A complex and neurodevelopmental disorders and neurodegeneration, we considered <italic toggle="yes">PTPA</italic> as the candidate disease-causing gene in this family.</p>
        <table-wrap position="float" id="awac326-T2">
          <label>Table 2</label>
          <caption>
            <p>Homozygous <italic toggle="yes">PTPA</italic> variants identified in the present study</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="center" span="1"/>
              <col valign="top" align="center" span="1"/>
              <col valign="top" align="center" span="1"/>
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="center" span="1"/>
              <col valign="top" align="center" span="1"/>
              <col valign="top" align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1">Family</th>
                <th align="center" rowspan="1" colspan="1">Chromosomal position<sup>a</sup></th>
                <th align="center" rowspan="1" colspan="1">Ref allele<sup>b</sup></th>
                <th align="center" rowspan="1" colspan="1">Alt allele<sup>c</sup></th>
                <th align="center" rowspan="1" colspan="1">cDNA<sup>d</sup></th>
                <th align="center" rowspan="1" colspan="1">Protein<sup>d</sup></th>
                <th align="center" rowspan="1" colspan="1">gnomAD v2.1.1</th>
                <th align="center" rowspan="1" colspan="1">CADD<sup>e</sup></th>
                <th align="center" rowspan="1" colspan="1">GERP<sup>e</sup></th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Family 1<break/>(South African)</td>
                <td rowspan="1" colspan="1">9:131904725</td>
                <td rowspan="1" colspan="1">T</td>
                <td rowspan="1" colspan="1">G</td>
                <td rowspan="1" colspan="1">c.893T&gt;G</td>
                <td rowspan="1" colspan="1">p.Met298Arg</td>
                <td rowspan="1" colspan="1">Absent</td>
                <td rowspan="1" colspan="1">32</td>
                <td rowspan="1" colspan="1">5.39</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Family 2<break/>(Libyan)</td>
                <td rowspan="1" colspan="1">9:131893865</td>
                <td rowspan="1" colspan="1">C</td>
                <td rowspan="1" colspan="1">A</td>
                <td rowspan="1" colspan="1">c.512C&gt;A</td>
                <td rowspan="1" colspan="1">p.Ala171Asp</td>
                <td rowspan="1" colspan="1">Absent</td>
                <td rowspan="1" colspan="1">23.6</td>
                <td rowspan="1" colspan="1">4.94</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="awac326-tblfn11">
              <p>
<sup>a</sup>Chromosomal position is given according to GRCh37/hg19.</p>
              <p>
<sup>b</sup>Ref allele=reference allele.</p>
              <p>
<sup>c</sup>Alt allele= alternative allele.</p>
              <p>
<sup>d</sup>Variants are annotated based on the PTPA transcript NM_178001.</p>
              <p>
<sup>e</sup>Predictions and scores across in silico algorithms were obtained via the Ensembl Variant Effect Predictor (VEP) v105<sup>40</sup>; CADD_phred_hg19<sup>54</sup>; GERP= genomic evolutionary rate profiling.<sup>55</sup></p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>Screening by means of Sanger sequencing of the first series of 200 unrelated probands with early-onset and/or recessive PD/parkinsonism did not reveal any additional cases with rare homozygous or compound heterozygous variants in <italic toggle="yes">PTPA</italic>.</p>
        <p>To assess the causality of <italic toggle="yes">PTPA</italic> in the FMPD cohort, we mined WES data from 87 families with AR PD and 502 isolated cases. Variants in PD-associated genes (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 2</xref>) were previously excluded. We identified a <italic toggle="yes">PTPA</italic> homozygous variant in the index case Subject F2-IV-5 (<xref rid="awac326-F1" ref-type="fig">Fig. 1B</xref> and <xref rid="awac326-T2" ref-type="table">Table 2</xref>) from a consanguineous Libyan family (Family 2). WES was subsequently performed in the affected brother, both parents and an unaffected brother of the index (<xref rid="awac326-F1" ref-type="fig">Fig. 1B</xref>). We searched for homozygous or compound heterozygous variants shared by the two affected siblings, heterozygous in both parents, and either absent or heterozygous in the unaffected sibling. We filtered all variants that possibly affected the cDNA or splice site regions with a MAF &lt; 1% in gnomAD.<sup><xref rid="awac326-B44" ref-type="bibr">44</xref></sup> As a result, only the homozygous variant in <italic toggle="yes">PTPA</italic>, c.512C &gt; A, p.Ala171Asp, remained, which co-segregates with disease in the family, and it was also confirmed by Sanger sequencing (<xref rid="awac326-F1" ref-type="fig">Fig. 1B</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 2</xref>). This variant, absent in gnomAD,<sup><xref rid="awac326-B44" ref-type="bibr">44</xref></sup> is predicted deleterious by many <italic toggle="yes">in silico</italic> algorithms (CADD<sup><xref rid="awac326-B54" ref-type="bibr">54</xref></sup> = 23.6; <xref rid="awac326-T2" ref-type="table">Table 2</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 6</xref>), and is localized in the 90th percentile constrained coding region.<sup><xref rid="awac326-B56" ref-type="bibr">56</xref></sup> Moreover, it affects an amino acid conserved up to zebrafish (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 3</xref>). Analysis of WES in the remaining 86 families and 502 isolated cases revealed no additional rare homozygous or compound heterozygous variants in <italic toggle="yes">PTPA</italic>.</p>
        <p>Considering both series together, the proportion of unrelated patients that underwent secondary screening and were found to carry bi-allelic <italic toggle="yes">PTPA</italic> variants was 1/42 (2.38%) for cases with familial early-onset parkinsonism and 1/7 (14.29%) for cases with early-onset parkinsonism and ID.</p>
        <p>The <italic toggle="yes">PTPA</italic> gene is extremely intolerant to LOF variants [pLI = 0.98 for ENST00000337738.1 (NM_178001)],<sup><xref rid="awac326-B44" ref-type="bibr">44</xref></sup> suggesting that LOF variants could be pathogenic even in heterozygous state. Therefore, we looked for LOF variants in the FMPD cohort and in the PD variant browser<sup><xref rid="awac326-B57" ref-type="bibr">57</xref></sup> (<xref rid="sup1" ref-type="supplementary-material">Supplementary material, Appendix 4</xref>) but no such variants were found in PD patients therein. Furthermore, we performed burden tests<sup><xref rid="awac326-B58" ref-type="bibr">58</xref></sup> using the publicly available data from the PD variant browser<sup><xref rid="awac326-B57" ref-type="bibr">57</xref></sup> to explore whether <italic toggle="yes">PTPA</italic> variants contribute to the risk of developing PD (<xref rid="sup1" ref-type="supplementary-material">Supplementary material, Appendix 4</xref>). We found no evidence of enrichment of <italic toggle="yes">PTPA</italic> variants in PD (<xref rid="sup1" ref-type="supplementary-material">Supplementary material, Appendix 4</xref>).</p>
      </sec>
      <sec id="awac326-s3.3">
        <title>p.Ala171Asp and p.Met298Arg PTPA variants cause decreased protein and RNA stability</title>
        <p>To investigate the effect of the identified disease-associated PTPA variants on PTPA protein and RNA stability, we assessed protein and RNA levels via western blotting and RT-qPCR in an overexpression model.</p>
        <p>First, we examined PTPA protein levels in cultured cells overexpressing wild-type PTPA (PTPA<sub>WT</sub>), p.Ala171Asp PTPA (PTPA<sub>A171D</sub>), p.Met298Arg PTPA (PTPA<sub>M298R</sub>), and a control plasmid (transfection control). Western blotting (<xref rid="awac326-F2" ref-type="fig">Fig. 2A</xref>) revealed a significant decrease in protein levels for both PTPA variants when compared to PTPA<sub>WT</sub>, with a stronger effect for PTPA<sub>A171D</sub> (<xref rid="awac326-F2" ref-type="fig">Fig. 2B</xref>).</p>
        <fig position="float" id="awac326-F2" fig-type="figure">
          <label>Figure 2</label>
          <caption>
            <p>
<bold>Comparison of protein and RNA levels of wild-type PTPA and the identified PTPA variants p.Ala171Asp PTPA and p.Met298Arg PTPA in cultured cells.</bold> (<bold>A</bold>) Representative western blot of protein extracts from cultured cells transfected with wild-type PTPA (PTPA<sub>WT</sub>), p.Ala171Asp PTPA (PTPA<sub>A171D</sub>), p.Met298Arg PTPA (PTPA<sub>M298R</sub>) and empty vector (Transfection Ctrl). Blots were probed for expression of PTPA and vinculin. (<bold>B</bold>) Quantification showing a significant decrease in PTPA levels in p.Ala171Asp and p.Met298Arg PTPA-expressing cells (<italic toggle="yes">n</italic> = 3). Mean (SD); PTPA<sub>WT</sub>: 1.00 (0.13); PTPA<sub>A171D</sub>: 0.06 (0.01); PTPA<sub>M298R</sub>: 0.81 (0.09); transfection control: 0.00 (0.00). (<bold>C</bold>) RT-qPCR analysis of <italic toggle="yes">PTPA</italic> in transfected cells, showing a significant decrease in <italic toggle="yes">PTPA</italic> expression in PTPA<sub>A171D</sub>, PTPA<sub>M298R</sub> and empty vector-expressing cells. Data represent relative normalized expression of <italic toggle="yes">PTPA</italic> mRNA. <italic toggle="yes">CLK2</italic> and <italic toggle="yes">COPS5</italic> were used as reference genes (<italic toggle="yes">n</italic> = 3). Mean (SD); PTPA<sub>WT</sub>: 1.00 (0.00); PTPA<sub>A171D</sub>: 0.74 (0.07); PTPA<sub>M298R</sub>: 0.77 (0.08); transfection control: 0.00 (0.00). (<bold>D</bold>) Representative western blot of PTPA in transfected cells treated with cycloheximide (CHX) for the indicated times. (<bold>E</bold>) Quantification of PTPA over cycloheximide treatment, showing a significant decrease in PTPA<sub>A171D</sub> compared to PTPA<sub>WT</sub> 2 h after treatment, indicating protein instability. The bars indicate mean PTPA levels per time point as percentage of cells treated at time = 0 h (<italic toggle="yes">n</italic> = 3). Error bars represent &#xB1; SD. Only significant changes *<italic toggle="yes">P</italic> &lt; 0.05, **<italic toggle="yes">P</italic> &lt; 0.01, ***<italic toggle="yes">P</italic> &lt; 0.001 and ****<italic toggle="yes">P</italic> &lt; 0.0001 are shown.</p>
          </caption>
          <graphic xlink:href="awac326f2" position="float"/>
        </fig>
        <p>To assess if RNA stability is involved in the observed reduction of PTPA variant protein levels, we performed RT-qPCR analyses in our overexpression model. We observed reduced relative amounts of <italic toggle="yes">PTPA</italic> transcript for both variants, indicating RNA instability (<xref rid="awac326-F2" ref-type="fig">Fig. 2C</xref>).</p>
        <p>Subsequently, to test whether the presence of PTPA variants affected protein stability, we tracked PTPA protein levels over time after blocking protein translation using cycloheximide (<xref rid="awac326-F2" ref-type="fig">Fig. 2C</xref>). This experiment revealed that 2 h after treatment, PTPA<sub>A171D</sub> displayed significantly lower PTPA levels when compared to PTPA<sub>WT</sub>, while PTPA<sub>M298R</sub> had a similar turnover rate to PTPA<sub>WT</sub>, with significantly reduced protein levels 3 h after treatment (<xref rid="awac326-F2" ref-type="fig">Fig. 2D</xref>).</p>
        <p>Last, we studied PTPA levels upon inhibition of the proteasome and autophagy-lysosome degradation pathways. Treatment for 4 h with MG-132, a potent proteasome inhibitor, led to a significant increase in PTPA<sub>A171D</sub> levels but had no effect on PTPA<sub>WT</sub> and PTPA<sub>M298R</sub> levels (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 4A and B</xref>). In contrast, PTPA<sub>WT</sub> and PTPA<sub>A171D</sub> were sensitive to induction of autophagy via Torin1 combined with lysosomal degradation inhibition via BafA1 for 4 h, whereas PTPA<sub>M298R</sub> remained unchanged, suggesting an abnormal interaction of this variant with the autophagy-lysosome pathway (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 4C and D</xref>).</p>
        <p>Taken together, these results show evidence for decreased RNA stability for both transcripts encoding PTPA<sub>A171D</sub> and PTPA<sub>M298R</sub> variants, and, additionally, decreased PTPA protein stability for PTPA<sub>A171D</sub>, mainly due to increased proteasomal degradation.</p>
      </sec>
      <sec id="awac326-s3.4">
        <title>p.Ala171Asp and p.Met298Arg PTPA variants are associated with impaired PP2A complex activation</title>
        <p>PP2A complex function is regulated both by post-translational modifications and by altering the levels of its components.<sup><xref rid="awac326-B59" ref-type="bibr">59&#x2013;63</xref></sup> To study the consequences of the expression of the identified PTPA variants on PP2A levels and activity, we studied protein and RNA levels of PP2A-C and quantified the PP2A Ser/Thr phosphatase activity.</p>
        <p>First, comparison of endogenous PP2A-C protein levels by western blotting in cultured cells expressing either PTPA<sub>WT</sub> or the identified PTPA variants (<xref rid="awac326-F3" ref-type="fig">Fig. 3A</xref>) demonstrated that overexpression of PTPA<sub>WT</sub> leads to a significant increase of endogenous PP2A-C levels, whereas overexpression of each of the PTPA variants does not (<xref rid="awac326-F3" ref-type="fig">Fig. 3B</xref>).</p>
        <fig position="float" id="awac326-F3" fig-type="figure">
          <label>Figure 3</label>
          <caption>
            <p>
<bold>Effect of wild-type PTPA and PTPA variants p.Ala171Asp and p.Met298Arg expression on PP2A complex levels and phosphatase activity.</bold> (<bold>A</bold>) Representative western blot of protein extracts from cultured cells transfected with wild-type PTPA (PTPA<sub>WT</sub>), p.Ala171Asp PTPA (PTPA<sub>A171D</sub>), p.Met298Arg PTPA (PTPA<sub>M298R</sub>) and empty vector (Transfection Ctrl). Blots were probed for expression of PP2A-C and vinculin (<bold>B</bold>) Quantification showing a significant decrease in PP2A-C levels in PTPA<sub>A171D</sub>, PTPA<sub>M298R</sub> and empty vector-expressing cells (<italic toggle="yes">n</italic> = 3). Mean (SD); PTPA<sub>WT</sub>: 1.00 (0.12); PTPA<sub>A171D</sub>: 0.67 (0.03); PTPA<sub>M298R</sub>: 0.74 (0.03); transfection control: 0.60 (0.09). (<bold>C</bold>) RT-qPCR analysis of <italic toggle="yes">PP2A-C</italic> in transfected cells. Quantification shows a mild but significant decrease of <italic toggle="yes">PP2A-C</italic> levels in PTPA<sub>A171D</sub>-expressing cells when compared to PTPA<sub>WT</sub>-expressing cells. Data represent relative normalized expression of <italic toggle="yes">PP2A-C</italic> mRNA. <italic toggle="yes">CLK2</italic> and <italic toggle="yes">COPS5</italic> were used as reference genes (<italic toggle="yes">n</italic> = 3). Mean (SD); PTPA<sub>WT</sub>: 1.00 (0.00); PTPA<sub>A171D</sub>: 0.85 (0.06); PTPA<sub>M298R</sub>: 0.93 (0.05); transfection control: 1.02 (0.10). (<bold>D</bold>) Quantification of Ser/Thr phosphatase activity assay in transfected cells, showing a significant decrease in activity in PTPA<sub>A171D</sub> and PTPA<sub>M298R</sub>-expressing cells (<italic toggle="yes">n</italic> = 3). Baseline represents pmoles of released phosphate from cells expressing an empty vector. Mean (SD); PTPA<sub>WT</sub>: 2626 (159.70); PTPA<sub>A171D</sub>: 1930 (91.24); PTPA<sub>M298R</sub>: 2139 (90.59); baseline: 1601.67. (<bold>E</bold>) Scheme representing PTPA-induced activation of PP2A complex phosphatase function by antagonizing the PP2A inhibitor PME-1, and proposed model where the identified PTPA variants p.Ala171Asp and p.Met298Arg are less efficient in inducing PP2A activation. Error bars represent &#xB1; SD. Only significant changes *<italic toggle="yes">P</italic> &lt; 0.05, **<italic toggle="yes">P</italic> &lt; 0.01 and ***<italic toggle="yes">P</italic> &lt; 0.001 are shown.</p>
          </caption>
          <graphic xlink:href="awac326f3" position="float"/>
        </fig>
        <p>To study the consequence of expression of wild-type or PTPA variants on <italic toggle="yes">PP2A-C</italic> RNA expression, we performed RT-qPCR in cultured cells. In contrast to what we observed at the protein level, <italic toggle="yes">PP2A-C</italic> mRNA levels were only mildly affected by PTPA overexpression, with only a significant reduction in cells expressing PTPA<sub>A171D</sub> (<xref rid="awac326-F3" ref-type="fig">Fig. 3C</xref>).</p>
        <p>PTPA is a powerful activator of PP2A Ser/Thr phosphatase activity.<sup><xref rid="awac326-B19" ref-type="bibr">19</xref>,<xref rid="awac326-B20" ref-type="bibr">20</xref></sup> We determined the effect of PTPA disease-associated variants on PP2A Ser/Thr phosphatase activity in a cell-free assay by quantifying the amount of released phosphate groups from the substrate by immunoprecipitated PP2A complexes. We observed that expression of the PTPA variants leads to a significant decrease in Ser/Thr phosphatase activity induction when compared to PTPA<sub>WT</sub> (<xref rid="awac326-F3" ref-type="fig">Fig. 3D</xref>). All quantifications were compared to baseline activity in cells expressing endogenous levels of PTPA<sub>WT</sub>. Taken together, these results indicate that PTPA<sub>A171D</sub> and PTPA<sub>M298R</sub> lead to decreased function of PTPA as a PP2A-activator (<xref rid="awac326-F3" ref-type="fig">Fig. 3E</xref>).</p>
      </sec>
      <sec id="awac326-s3.5">
        <title>PTPA loss-of-function induces a locomotor dysfunction in <italic toggle="yes">Drosophila</italic> that is L-DOPA-reversible</title>
        <p>To determine the effect of <italic toggle="yes">PTPA</italic> LOF <italic toggle="yes">in vivo</italic>, we turned to <italic toggle="yes">Drosophila</italic> as a model system. We assayed locomotor activity using the classic negative geotaxis climbing assay and measured performance at different ages upon pan-neuronal RNAi-mediated <italic toggle="yes">ptpa</italic> knock-down compared to controls; <italic toggle="yes">prkn</italic> knock-down was used as a positive control and <italic toggle="yes">nsmase</italic> knock-down as a negative control. No phenotype was observed in 10-day-old flies for any of the lines. At 20 days of age, locomotor dysfunction was observed for the <italic toggle="yes">prkn</italic> and the <italic toggle="yes">ptpa</italic> RNAi strains. The proportion of flies that did not reach the 5 cm threshold was significantly higher in both lines compared to <italic toggle="yes">nsmase</italic> knock-down. Behavioural tests at Day 35 revealed a more severe motor impairment upon knock-down of <italic toggle="yes">prkn</italic> and <italic toggle="yes">ptpa</italic> (<xref rid="awac326-F4" ref-type="fig">Fig. 4</xref>).</p>
        <fig position="float" id="awac326-F4" fig-type="figure">
          <label>Figure 4</label>
          <caption>
            <p>
<bold>Effect of <italic toggle="yes">ptpa</italic> knock-down on <italic toggle="yes">D. melanogaster</italic> negative geotaxis measured by the climbing test.</bold> Comparative climbing test of three different UAS constructs (<italic toggle="yes">prkn, ptpa, nsmase</italic>) with and without L-DOPA treatment. <italic toggle="yes">prkn</italic> is used as positive control (significant locomotor impairment). <italic toggle="yes">nsmase</italic> is used as a negative control (no locomotor impairment). Climbing test performed at Days 10, 20, and 35 represented as proportion of flies that did not reach the 5 cm threshold. No significant difference is observed in locomotor behaviour between <italic toggle="yes">ptpa</italic> and controls on Day 10. Significant locomotor defect was observed at Days 20 and 35 for the <italic toggle="yes">ptpa</italic> and <italic toggle="yes">prkn</italic> lines compared to the negative control <italic toggle="yes">nsmase</italic>. This defect was significantly corrected with L-DOPA treatment. Significant comparisons are indicated by an asterisk. *<italic toggle="yes">P</italic> &lt; 0.05. Human and <italic toggle="yes">Drosophila</italic> orthologues: <italic toggle="yes">PRKN</italic> (human)/<italic toggle="yes">prkn</italic> (<italic toggle="yes">D. melanogaster</italic>); <italic toggle="yes">PTPA</italic> (human)/<italic toggle="yes">ptpa</italic> (<italic toggle="yes">D. melanogaster</italic>); <italic toggle="yes">SMPD2</italic> (human)/<italic toggle="yes">nsmase</italic> (<italic toggle="yes">D. melanogaster</italic>).</p>
          </caption>
          <graphic xlink:href="awac326f4" position="float"/>
        </fig>
        <p>In parallel, we analysed the same lines with food supplemented with L-DOPA. This treatment completely rescued the motor phenotype in the <italic toggle="yes">prkn</italic> and <italic toggle="yes">ptpa</italic> lines at Days 20 and 35 (<xref rid="awac326-F4" ref-type="fig">Fig. 4</xref>). In contrast, L-DOPA treatment had no effect on locomotor behaviour in the <italic toggle="yes">nsmase</italic> line.</p>
        <p>Taken together, these results suggest that pan-neuronal knock-down of <italic toggle="yes">ptpa</italic> leads to an age-dependent motor impairment. This defect appears to be dopamine-dependent, as it is reversible with L-DOPA treatment.</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="awac326-s4">
      <title>Discussion</title>
      <p>We present clinical, genetic, and functional studies in two families of South African and Libyan origin with early-onset parkinsonism and ID, associated with variants in the <italic toggle="yes">PTPA</italic> gene. To our knowledge, this is the first study reporting a monogenic disorder caused by <italic toggle="yes">PTPA</italic> variants. All four affected homozygotes in this study manifested juvenile-onset parkinsonism and ID. The parkinsonism was progressive, with marked sustained response to levodopa, and in some patients, levodopa-induced dyskinesias and good response to STN-DBS. The intellectual impairment was mild or moderate in these different patients, possibly unmasked with more complex tasks at school, and there was no evidence of marked progression of the cognitive status over time in any of the four patients. Unfortunately, cognitive evaluation using standard rating scales was not available in the siblings in Family 1. However, both siblings had mild ID and they remained independent in basic activities of daily living.</p>
      <p>Based on the reported molecular interplay between PP2A and alpha-synuclein, tau, and LRRK2, it is possible that pathological protein aggregation is present in the brains of our patients with <italic toggle="yes">PTPA</italic> variants. Unfortunately, brain pathology is not available, and whether they have alpha-synuclein, tau and/or other types of protein aggregates remains unknown. Similarly, brain SPECT (DaTSCAN) or PET studies were not available. However, the response to levodopa in both families and STN-DBS in Family 1, as well as the development of levodopa-induced dyskinesias, are in line with the presence of severe presynaptic nigrostriatal dopaminergic deficit.</p>
      <p>Further studies in additional patient series and populations will contribute to assess the prevalence of <italic toggle="yes">PTPA</italic> variants in early-onset PD or parkinsonism with ID, and further characterize the associated phenotypes. Regarding the common forms of late-onset PD, we did not find evidence for enrichment of <italic toggle="yes">PTPA</italic> variants in PD cases in the PD variant browser,<sup><xref rid="awac326-B57" ref-type="bibr">57</xref></sup> and no association of common variants at the <italic toggle="yes">PTPA</italic> locus with PD is known from the latest meta-analysis of genome wide association studies.<sup><xref rid="awac326-B64" ref-type="bibr">64</xref></sup></p>
      <p>A variable co-occurrence of parkinsonism and ID has previously been observed in carriers of pathogenic variants in other established or nominated genes, including <italic toggle="yes">DNAJC6</italic>,<sup><xref rid="awac326-B65" ref-type="bibr">65</xref></sup><italic toggle="yes">RAB39B</italic>,<sup><xref rid="awac326-B66" ref-type="bibr">66</xref>,<xref rid="awac326-B67" ref-type="bibr">67</xref></sup><italic toggle="yes">NR4A2/NURR1</italic>,<sup><xref rid="awac326-B68" ref-type="bibr">68</xref></sup><italic toggle="yes">WDR45</italic>,<sup><xref rid="awac326-B69" ref-type="bibr">69</xref>,<xref rid="awac326-B70" ref-type="bibr">70</xref></sup> and <italic toggle="yes">PTRHD1</italic>,<sup><xref rid="awac326-B71" ref-type="bibr">71</xref>,<xref rid="awac326-B72" ref-type="bibr">72</xref></sup> but the neurobiological mechanisms remain incompletely understood. Some of these genes have been implicated in ubiquitous pathways such as vesicular trafficking,<sup><xref rid="awac326-B67" ref-type="bibr">67</xref>,<xref rid="awac326-B73" ref-type="bibr">73&#x2013;75</xref></sup> autophagy,<sup><xref rid="awac326-B76" ref-type="bibr">76&#x2013;78</xref></sup> and the ubiquitin-proteasome system,<sup><xref rid="awac326-B79" ref-type="bibr">79</xref></sup> proposed to be dysfunctional both in parkinsonism/PD and ID.<sup><xref rid="awac326-B80" ref-type="bibr">80&#x2013;85</xref></sup> Future work will determine whether these or other pathways are perturbed in patients with <italic toggle="yes">PTPA</italic> variants.</p>
      <p>Interestingly, rare variants in genes encoding for different subunits/regulators of the PP2A complex have been associated with neurodevelopmental disorders. Patients with <italic toggle="yes">PPP2R1A</italic> variants present with developmental delay ranging from mild learning difficulties to severe ID,<sup><xref rid="awac326-B86" ref-type="bibr">86&#x2013;88</xref></sup> and other features such as seizures, hypotonia, and hypermobile joints.<sup><xref rid="awac326-B87" ref-type="bibr">87</xref></sup> Patients with <italic toggle="yes">PPP2CA</italic> variants manifest mild to severe ID, developmental delay, behavioural problems, epilepsy, hypotonia, and structural brain abnormalities.<sup><xref rid="awac326-B89" ref-type="bibr">89</xref></sup> Variants in other PP2A-related genes, including <italic toggle="yes">IGBP1</italic>,<sup><xref rid="awac326-B90" ref-type="bibr">90</xref>,<xref rid="awac326-B91" ref-type="bibr">91</xref></sup><italic toggle="yes">PPP2R2C</italic>,<sup><xref rid="awac326-B92" ref-type="bibr">92</xref></sup><italic toggle="yes">PPP2R5C</italic>,<sup><xref rid="awac326-B93" ref-type="bibr">93</xref></sup><italic toggle="yes">PPP2R5B</italic>,<sup><xref rid="awac326-B93" ref-type="bibr">93&#x2013;95</xref></sup> and <italic toggle="yes">PPP2R2B</italic>,<sup><xref rid="awac326-B96" ref-type="bibr">96</xref></sup> have been described in ID but in some cases the evidence is inconclusive, as they are often found in unique cases or families. More importantly, rare variants in <italic toggle="yes">PPP2R5D</italic>, previously established in ID and developmental delay with variable occurrence of other clinical features,<sup><xref rid="awac326-B88" ref-type="bibr">88</xref>,<xref rid="awac326-B93" ref-type="bibr">93</xref>,<xref rid="awac326-B97" ref-type="bibr">97</xref></sup> were recently identified in patients with early-onset levodopa-responsive parkinsonism.<sup><xref rid="awac326-B93" ref-type="bibr">93</xref>,<xref rid="awac326-B98" ref-type="bibr">98&#x2013;101</xref></sup> Neuropathological examination in a single patient with early-onset parkinsonism, mild ID, developmental delay, and the <italic toggle="yes">PPP2R5D</italic> p.E200K variant revealed severe neuronal loss and gliosis in the substantia nigra pars compacta with absence of Lewy body pathology.<sup><xref rid="awac326-B98" ref-type="bibr">98</xref></sup></p>
      <p>Our <italic toggle="yes">in vitro</italic> studies show several defects in the identified PTPA variants. First, both variants present a reduction in PTPA mRNA levels (<xref rid="awac326-F2" ref-type="fig">Fig. 2C</xref>). This reduction cannot be explained by defects during pre-mRNA formation since these experiments were performed using PTPA cDNA lacking the 5&#x2032; and 3&#x2032; untranslated regions. However, several additional mechanisms have been described where single nucleotide variants lead to decreased RNA stability, and many of these have been associated with diseases, including PD.<sup><xref rid="awac326-B102" ref-type="bibr">102</xref></sup> Namely, single nucleotide variants can add or remove binding sites for microRNAs and RNA-binding proteins,<sup><xref rid="awac326-B103" ref-type="bibr">103</xref>,<xref rid="awac326-B104" ref-type="bibr">104</xref></sup> or strongly affect mRNA secondary structures, leading to changes in mRNA levels and functionality.<sup><xref rid="awac326-B105" ref-type="bibr">105</xref>,<xref rid="awac326-B106" ref-type="bibr">106</xref></sup></p>
      <p>In addition to decreased <italic toggle="yes">PTPA</italic> mRNA levels, both variants present lower protein levels (<xref rid="awac326-F2" ref-type="fig">Fig. 2A and B</xref>). For the PTPA<sub>A171D</sub> variant, this effect can be explained by both the lower transcript levels and the decreased protein stability assessed upon cycloheximide treatment (<xref rid="awac326-F2" ref-type="fig">Fig. 2D and E</xref>). This increased degradation rate can be potentially explained by more efficient proteasomal degradation (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 4A and B</xref>), which would be consistent with an abnormal PTPA protein folding due to the presence of p.Ala171Asp. On the other hand, we did not find evidence for protein instability for the PTPA<sub>M298R</sub> variant, which presented a similar turnover rate to PTPA<sub>WT</sub> upon cycloheximide treatment (<xref rid="awac326-F2" ref-type="fig">Fig. 2D and E</xref>). Therefore, it is possible that the decrease in protein levels for this variant is solely due to lower mRNA levels. Interestingly however, this variant shows a defective interaction with the autophagosomal degradation pathway (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 4C and D</xref>), suggesting that this variant is being disposed via an alternative proteasome- and lysosome-independent pathway.</p>
      <p>Importantly, although the two variants have different effects on PTPA, both lead to a similar outcome, which is the decrease in PP2A phosphatase levels and activity (<xref rid="awac326-F3" ref-type="fig">Fig. 3</xref>). While overexpression of PTPA<sub>WT</sub> leads to increased endogenous PP2A-C protein (but not mRNA) levels, overexpression of PTPA<sub>M298R</sub> and PTPA<sub>A171D</sub> fails to do so. PP2A-C levels have been described to be under a complex regulatory control at the translational level, via incompletely understood mechanisms.<sup><xref rid="awac326-B59" ref-type="bibr">59&#x2013;63</xref></sup> However, PP2A-C methylation, which is highly regulated by PTPA, is a well-known dynamic process that determines PP2A-C stability and function.<sup><xref rid="awac326-B15" ref-type="bibr">15</xref>,<xref rid="awac326-B16" ref-type="bibr">16</xref>,<xref rid="awac326-B107" ref-type="bibr">107</xref></sup> We hypothesize that overexpression of PTPA<sub>WT</sub> might lead to increased methylation and stability of PP2A-C in PP2A complexes, decreasing its degradation rate; mechanism that is lacking when overexpressing the disease-associated variants, possibly due to decreased binding or activity. Additional work remains ahead to further elucidate the consequences of these variants in the structure of the PP2A complex.</p>
      <p>The stimulating role of PTPA on PP2A Ser/Thr phosphatase function is arguably the most relevant function for PTPA.<sup><xref rid="awac326-B15" ref-type="bibr">15</xref>,<xref rid="awac326-B16" ref-type="bibr">16</xref>,<xref rid="awac326-B19" ref-type="bibr">19</xref></sup> Another function described for PTPA is to stimulate the basal tyrosyl phosphatase activity of PP2A, even though no known endogenous substrates have yet been identified.<sup><xref rid="awac326-B16" ref-type="bibr">16</xref>,<xref rid="awac326-B108" ref-type="bibr">108</xref></sup> It is therefore possible that defects in PTPA impair PP2A function by additional mechanisms. Last, it is unknown whether the identified <italic toggle="yes">PTPA</italic> variants cause disease by affecting the metabolism/aggregation of alpha-synuclein, tau, tyrosine hydroxylase, or other proteins involved in neurodegeneration, thus further work is warranted. Taken together, our findings from overexpression experiments could indicate that both the identified variants are hypomorphic, and therefore point to PTPA LOF and impaired PP2A stimulation as a common pathogenic mechanism.</p>
      <p>
<italic toggle="yes">Drosophila melanogaster</italic> has proven useful for modelling certain aspects of several neurodegenerative disorders, including PD.<sup><xref rid="awac326-B109" ref-type="bibr">109&#x2013;111</xref></sup> Negative geotaxis tested with the climbing assay is a robust behavioural test able to detect subtle changes in flies&#x2019; locomotion. Our assays show that neuronal-specific knock-down of the <italic toggle="yes">Drosophila PTPA</italic> gene orthologue is sufficient to induce a significant locomotor defect in adult mutant flies when compared to the negative control line from Day 20 onwards (<xref rid="awac326-F4" ref-type="fig">Fig. 4</xref>). The severity of the phenotype appears to be age-dependent, which might reflect the progressive nature of the underlying neuronal dysfunction or degeneration, similar to the progressive course of parkinsonism in the <italic toggle="yes">PTPA</italic> variant carriers in this study. This locomotor impairment in <italic toggle="yes">ptpa</italic> knock-down flies is also dopamine-dependent, as it is fully corrected after L-DOPA treatment, suggesting a possible connection between <italic toggle="yes">ptpa</italic> expression and the function of dopaminergic neurons. Interestingly, since <italic toggle="yes">Drosophila</italic> has no homologue of the <italic toggle="yes">SNCA</italic> gene,<sup><xref rid="awac326-B109" ref-type="bibr">109</xref></sup> abnormal phosphorylation levels of other PP2A targets might be responsible for the observed locomotor dysfunction.</p>
      <p>To conclude, we report the identification of <italic toggle="yes">PTPA</italic> as a novel gene associated with juvenile-onset parkinsonism and ID and point to PTPA LOF and impaired activity of the PP2A complex as the most likely pathogenic mechanism for the identified variants. Additional work might provide further insights into the mechanism of the disease caused by <italic toggle="yes">PTPA</italic> variants, and perhaps to the involvement of PTPA and the PP2A complex in the pathogenesis of more common forms of neurodegeneration.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supplementary Material</title>
      <supplementary-material id="sup1" position="float" content-type="local-data">
        <label>awac326_Supplementary_Data</label>
        <media xlink:href="awac326_supplementary_data.zip">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="ack1">
      <title>Acknowledgements</title>
      <p>We are indebted to the patients participating in this study as well as their families. We thank the DNA and Cell Bank of the ICM Brain Institute for sample preparation, the iGenSeq plateform for exome sequencing and the DAC core facility for bioinformatics analyses. We also thank Pierre Tissier and Aymeric Millecamps for building a device for semi-automated climbing tests. We are grateful to Dr Andrew Singleton for providing some of the WES data through the Intramural Research Program of the National Institute on Aging, National Institutes of Health, Department of Health and Human Services. We acknowledge the support of the DST-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.</p>
    </ack>
    <sec id="awac326-s8">
      <title>Funding</title>
      <p>This work was supported by a grant (SPF-1870) from the Stichting ParkinsonFonds (The Netherlands) to VB; the Fondation pour la Recherche M&#xE9;dicale (FRM, MND202004011718), PTC Therapeutics, the Fondation de France, France-Parkinson Association, la F&#xE9;d&#xE9;ration pour la Recherche sur le Cerveau (FRC) and the French program &#x2018;Investissements d&#x2019;avenir&#x2019; (ANR-10-IAIHU-06) to AB; and grants from the South African Medical Research Council (Self-Initiated Research Grant) and the National Research Foundation of South Africa (Grant Number 129249) to SB.</p>
    </sec>
    <sec sec-type="COI-statement" id="awac326-s9">
      <title>Competing interests</title>
      <p>V.B. receives honoraria from Elsevier Ltd. for serving as co-Editor-in-Chief of Parkinsonism &amp; Related Disorders. He also received speaking honoraria from the International Parkinson and Movement Disorder Society, and honoraria as Chair of the MDS International Congress Program Committee (2019&#x2013;2021).</p>
    </sec>
    <sec id="awac326-s10">
      <title>Supplementary material</title>
      <p>
<xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref> is available at <italic toggle="yes">Brain</italic> online.</p>
    </sec>
    <app-group>
      <app id="awac326-app1">
        <title>Appendix 1</title>
        <sec id="awac326-s5">
          <title>French and Mediterranean clinicians&#x2019; network for Parkinson&#x2019;s disease genetics (the PDG group) collaborators</title>
          <p>Full details are provided in the <xref rid="sup1" ref-type="supplementary-material">Supplementary material, Appendix 1</xref>.</p>
        </sec>
        <sec id="awac326-s6">
          <title>French PDG collaborators</title>
          <p>Yves Agid, Mathieu Anheim, Michel Borg, Alexis Brice, Emmanuel Broussolle, Jean-Christophe Corvol, Philippe Damier, Luc Defebvre, Alexandra D&#xFC;rr, Franck Durif, Jean Luc Houeto, Paul Krack, Stephan Klebe, Suzanne Lesage, Ebba Lohmann, Maria Martinez, Graziella Mangone, Louise-Laure Mariani, Pierre Pollak, Olivier Rascol, Fran&#xE7;ois Tison, Christine Tranchant, Marc V&#xE9;rin, Fran&#xE7;ois Viallet, and Marie Vidailhet.</p>
        </sec>
        <sec id="awac326-s7">
          <title>Collaborators from Mediterranean countries</title>
          <p>Ebba Lohmann, Murat Emre, Hasmet Hanagasi, Basar Bilgic, Bedia Marangozo&#x11F;lu, Mustapha Benmahdjoub, Mohammed Arezki, Sofiane A. Bouchetara, Traki Benhassine, Meriem Tazir, Mouna Ben Djebara, Riadh Gouider, Sawssan Ben Romdhan, Chokri Mhiri, Ahmed Bouhouche.</p>
        </sec>
      </app>
    </app-group>
    <app-group>
      <app id="awac326-app2">
        <title>Appendix 2</title>
        <sec id="awac326-s11">
          <title>Collaborators of the International Parkinsonism Genetics Network</title>
          <p>Full details are provided in the <xref rid="sup1" ref-type="supplementary-material">Supplementary material, Appendix 2</xref>.</p>
          <p>Vincenzo Bonifati, Wim Mandemakers, Anneke J. A. Kievit, Agnita J. W. Boon, Joaquim J. Ferreira, Leonor Correia Guedes, Murat Emre, Hasmet A. Hanagasi, Basar Bilgic, Zeynep Tufekcioglu, B&#xFC;lent Elibol, Okan Do&#x11F;u, Murat Gultekin, Hsin F. Chien, Egberto Barbosa, Laura Bannach Jardim, Carlos R. M. Rieder, Hsiu-Chen Chang, Chin-Song Lu, Yah-Huei Wu-Chou, Tu-Hsueh Yeh, Leonardo Lopiano, Cristina Tassorelli, Claudio Pacchetti, Cristoforo Comi, Francesco Raudino, Laura Bertolasi, Michele Tinazzi, Alberto Bonizzato, Carlo Ferracci, Roberto Marconi, Marco Guidi, Marco Onofrj, Astrid Thomas, Nicola Vanacore, Giuseppe Meco, Edito Fabrizio, Giovanni Fabbrini, Alfredo Berardelli, Fabrizio Stocchi, Laura Vacca, Paolo Barone, Marina Picillo, Giuseppe De Michele, Chiara Criscuolo, Michele De Mari, Claudia Dell'Aquila, Giovanni Iliceto, Vincenzo Toni, Giorgio Trianni, Valeria Saddi, Gianni Cossu, Maurizio Melis.</p>
        </sec>
      </app>
    </app-group>
    <ref-list id="ref1">
      <title>References</title>
      <ref id="awac326-B1">
        <label>1</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Polymeropoulos</surname>
<given-names>MH</given-names>
</string-name>, <string-name><surname>Lavedan</surname><given-names>C</given-names></string-name>, <string-name><surname>Leroy</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Mutation in the alpha-synuclein gene identified in families with Parkinson's disease</article-title>. <source>Science</source>. <year>1997</year>;<volume>276</volume>:<fpage>2045</fpage>&#x2013;<lpage>2047</lpage>.<pub-id pub-id-type="pmid">9197268</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B2">
        <label>2</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Pais&#xE1;n-Ru&#xED;z</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Jain</surname><given-names>S</given-names></string-name>, <string-name><surname>Evans</surname><given-names>EW</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease</article-title>. <source>Neuron</source>. <year>2004</year>;<volume>44</volume>:<fpage>595</fpage>&#x2013;<lpage>600</lpage>.<pub-id pub-id-type="pmid">15541308</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B3">
        <label>3</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zimprich</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Biskup</surname><given-names>S</given-names></string-name>, <string-name><surname>Leitner</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology</article-title>. <source>Neuron</source>. <year>2004</year>;<volume>44</volume>:<fpage>601</fpage>&#x2013;<lpage>607</lpage>.<pub-id pub-id-type="pmid">15541309</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B4">
        <label>4</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Vilari&#xF1;o-G&#xFC;ell</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Wider</surname><given-names>C</given-names></string-name>, <string-name><surname>Ross</surname><given-names>OA</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>VPS35 Mutations in Parkinson disease</article-title>. <source>Am J Hum Genet</source>. <year>2011</year>;<volume>89</volume>:<fpage>162</fpage>&#x2013;<lpage>167</lpage>.<pub-id pub-id-type="pmid">21763482</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B5">
        <label>5</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zimprich</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Benet-Pag&#xE8;s</surname><given-names>A</given-names></string-name>, <string-name><surname>Struhal</surname><given-names>W</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease</article-title>. <source>Am J Hum Genet</source>. <year>2011</year>;<volume>89</volume>:<fpage>168</fpage>&#x2013;<lpage>175</lpage>.<pub-id pub-id-type="pmid">21763483</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B6">
        <label>6</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kitada</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Asakawa</surname><given-names>S</given-names></string-name>, <string-name><surname>Hattori</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism</article-title>. <source>Nature</source>. <year>1998</year>;<volume>392</volume>:<fpage>605</fpage>&#x2013;<lpage>608</lpage>.</mixed-citation>
      </ref>
      <ref id="awac326-B7">
        <label>7</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Valente</surname>
<given-names>EM</given-names>
</string-name>, <string-name><surname>Abou-Sleiman</surname><given-names>PM</given-names></string-name>, <string-name><surname>Caputo</surname><given-names>V</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Hereditary early-onset Parkinson's disease caused by mutations in <italic toggle="yes">PINK1</italic></article-title>. <source>Science</source>. <year>2004</year>;<volume>304</volume>:<fpage>1158</fpage>&#x2013;<lpage>1160</lpage>.</mixed-citation>
      </ref>
      <ref id="awac326-B8">
        <label>8</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bonifati</surname>
<given-names>V</given-names>
</string-name>, <string-name><surname>Rizzu</surname><given-names>P</given-names></string-name>, <string-name><surname>van Baren</surname><given-names>MJ</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Mutations in the <italic toggle="yes">DJ-1</italic> gene associated with autosomal recessive early-onset parkinsonism</article-title>. <source>Science</source>. <year>2003</year>;<volume>299</volume>:<fpage>256</fpage>&#x2013;<lpage>259</lpage>.</mixed-citation>
      </ref>
      <ref id="awac326-B9">
        <label>9</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tung</surname>
<given-names>HY</given-names>
</string-name>, <string-name><surname>Alemany</surname><given-names>S</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>P</given-names></string-name></person-group>. <article-title>The protein phosphatases involved in cellular regulation. 2. Purification, subunit structure and properties of protein phosphatases-2A0, 2A1, and 2A2 from rabbit skeletal muscle</article-title>. <source>Eur J Biochem</source>. <year>1985</year>;<volume>148</volume>:<fpage>253</fpage>&#x2013;<lpage>263</lpage>.</mixed-citation>
      </ref>
      <ref id="awac326-B10">
        <label>10</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wlodarchak</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Xing</surname><given-names>Y</given-names></string-name></person-group>. <article-title>PP2A as a master regulator of the cell cycle</article-title>. <source>Crit Rev Biochem Mol Biol</source>. <year>2016</year>;<volume>51</volume>:<fpage>162</fpage>&#x2013;<lpage>184</lpage>.<pub-id pub-id-type="pmid">26906453</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B11">
        <label>11</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lee</surname>
<given-names>WJ</given-names>
</string-name>, <string-name><surname>Kim</surname><given-names>DU</given-names></string-name>, <string-name><surname>Lee</surname><given-names>MY</given-names></string-name>, <string-name><surname>Choi</surname><given-names>KY</given-names></string-name></person-group>. <article-title>Identification of proteins interacting with the catalytic subunit of PP2A by proteomics</article-title>. <source>Proteomics</source>. <year>2007</year>;<volume>7</volume>:<fpage>206</fpage>&#x2013;<lpage>214</lpage>.<pub-id pub-id-type="pmid">17163575</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B12">
        <label>12</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hoffman</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Taleski</surname><given-names>G</given-names></string-name>, <string-name><surname>Sontag</surname><given-names>E</given-names></string-name></person-group>. <article-title>The protein serine/threonine phosphatases PP2A, PP1 and calcineurin: a triple threat in the regulation of the neuronal cytoskeleton</article-title>. <source>Mol Cell Neurosci</source>. <year>2017</year>;<volume>84</volume>:<fpage>119</fpage>&#x2013;<lpage>131</lpage>.<pub-id pub-id-type="pmid">28126489</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B13">
        <label>13</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Van Hoof</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Goris</surname><given-names>J</given-names></string-name></person-group>. <article-title>Phosphatases in apoptosis: to be or not to be, PP2A is in the heart of the question</article-title>. <source>Biochim Biophys Acta</source>. <year>2003</year>;<volume>1640</volume>(<issue>2-3</issue>):<fpage>97</fpage>&#x2013;<lpage>104</lpage>.<pub-id pub-id-type="pmid">12729918</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B14">
        <label>14</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sandal</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Jong</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Merrill</surname><given-names>RA</given-names></string-name>, <string-name><surname>Song</surname><given-names>J</given-names></string-name>, <string-name><surname>Strack</surname><given-names>S</given-names></string-name></person-group>. <article-title>Protein phosphatase 2A - structure, function and role in neurodevelopmental disorders</article-title>. <source>J Cell Sci</source>. <year>2021</year>;<volume>134</volume>:<fpage>jcs248187</fpage>.<pub-id pub-id-type="pmid">34228795</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B15">
        <label>15</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Guo</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Stanevich</surname><given-names>V</given-names></string-name>, <string-name><surname>Wlodarchak</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Structural basis of PP2A activation by PTPA, an ATP-dependent activation chaperone</article-title>. <source>Cell Res</source>. <year>2014</year>;<volume>24</volume>:<fpage>190</fpage>&#x2013;<lpage>203</lpage>.<pub-id pub-id-type="pmid">24100351</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B16">
        <label>16</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Fellner</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Lackner</surname><given-names>DH</given-names></string-name>, <string-name><surname>Hombauer</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>A novel and essential mechanism determining specificity and activity of protein phosphatase 2A (PP2A) in vivo</article-title>. <source>Genes Dev</source>. <year>2003</year>;<volume>17</volume>:<fpage>2138</fpage>&#x2013;<lpage>2150</lpage>.<pub-id pub-id-type="pmid">12952889</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B17">
        <label>17</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Xing</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Structural mechanism of demethylation and inactivation of protein phosphatase 2A</article-title>. <source>Cell</source>. <year>2008</year>;<volume>133</volume>:<fpage>154</fpage>&#x2013;<lpage>163</lpage>.<pub-id pub-id-type="pmid">18394995</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B18">
        <label>18</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kaur</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Westermarck</surname><given-names>J</given-names></string-name></person-group>. <article-title>Regulation of protein phosphatase 2A (PP2A) tumor suppressor function by PME-1</article-title>. <source>Biochem Soc Trans</source>. <year>2016</year>;<volume>44</volume>:<fpage>1683</fpage>&#x2013;<lpage>1693</lpage>.<pub-id pub-id-type="pmid">27913678</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B19">
        <label>19</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Longin</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Jordens</surname><given-names>J</given-names></string-name>, <string-name><surname>Martens</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>An inactive protein phosphatase 2A population is associated with methylesterase and can be re-activated by the phosphotyrosyl phosphatase activator</article-title>. <source>Biochem J</source>. <year>2004</year>;<volume>380</volume>(<issue>1</issue>):<fpage>111</fpage>&#x2013;<lpage>119</lpage>.<pub-id pub-id-type="pmid">14748741</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B20">
        <label>20</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Stanevich</surname>
<given-names>V</given-names>
</string-name>, <string-name><surname>Jiang</surname><given-names>L</given-names></string-name>, <string-name><surname>Satyshur</surname><given-names>KA</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>The structural basis for tight control of PP2A methylation and function by LCMT-1</article-title>. <source>Mol Cell</source>. <year>2011</year>;<volume>41</volume>:<fpage>331</fpage>&#x2013;<lpage>342</lpage>.<pub-id pub-id-type="pmid">21292165</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B21">
        <label>21</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhang</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Huang</surname><given-names>ZX</given-names></string-name>, <string-name><surname>Bao</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Phosphotyrosyl phosphatase activator facilitates localization of Miranda through dephosphorylation in dividing neuroblasts</article-title>. <source>Development</source>. <year>2016</year>;<volume>143</volume>:<fpage>35</fpage>&#x2013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">26586222</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B22">
        <label>22</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Van Hoof</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Janssens</surname><given-names>V</given-names></string-name>, <string-name><surname>De Baere</surname><given-names>I</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>The Saccharomyces cerevisiae phosphotyrosyl phosphatase activator proteins are required for a subset of the functions disrupted by protein phosphatase 2A mutations</article-title>. <source>Exp Cell Res</source>. <year>2001</year>;<volume>264</volume>:<fpage>372</fpage>&#x2013;<lpage>387</lpage>.<pub-id pub-id-type="pmid">11262194</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B23">
        <label>23</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rempola</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Kaniak</surname><given-names>A</given-names></string-name>, <string-name><surname>Migdalski</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Functional analysis of RRD1 (YIL153w) and RRD2 (YPL152w), which encode two putative activators of the phosphotyrosyl phosphatase activity of PP2A in saccharomyces cerevisiae</article-title>. <source>Mol Gen Genet</source>. <year>2000</year>;<volume>262</volume>:<fpage>1081</fpage>&#x2013;<lpage>1092</lpage>.<pub-id pub-id-type="pmid">10660069</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B24">
        <label>24</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Park</surname>
<given-names>HJ</given-names>
</string-name>, <string-name><surname>Lee</surname><given-names>KW</given-names></string-name>, <string-name><surname>Oh</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Protein phosphatase 2A and its methylation modulating enzymes LCMT-1 and PME-1 are dysregulated in tauopathies of progressive supranuclear palsy and Alzheimer disease</article-title>. <source>J Neuropathol Exp Neurol</source>. <year>2018</year>;<volume>77</volume>:<fpage>139</fpage>&#x2013;<lpage>148</lpage>.<pub-id pub-id-type="pmid">29281045</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B25">
        <label>25</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lee</surname>
<given-names>KW</given-names>
</string-name>, <string-name><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name><surname>Junn</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Enhanced phosphatase activity attenuates &#x3B1;-synucleinopathy in a mouse model</article-title>. <source>J Neurosci</source>. <year>2011</year>;<volume>31</volume>:<fpage>6963</fpage>&#x2013;<lpage>6971</lpage>.</mixed-citation>
      </ref>
      <ref id="awac326-B26">
        <label>26</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Saraf</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Oberg</surname><given-names>EA</given-names></string-name>, <string-name><surname>Strack</surname><given-names>S</given-names></string-name></person-group>. <article-title>Molecular determinants for PP2A substrate specificity: charged residues mediate dephosphorylation of tyrosine hydroxylase by the PP2A/B&#x2019; regulatory subunit</article-title>. <source>Biochemistry</source>. <year>2010</year>;<volume>49</volume>:<fpage>986</fpage>&#x2013;<lpage>995</lpage>.</mixed-citation>
      </ref>
      <ref id="awac326-B27">
        <label>27</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Drouyer</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Bolliger</surname><given-names>MF</given-names></string-name>, <string-name><surname>Lobbestael</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation</article-title>. <source>Neurobiol Dis</source>. <year>2021</year>;<volume>157</volume>:<fpage>105426</fpage>.</mixed-citation>
      </ref>
      <ref id="awac326-B28">
        <label>28</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sontag</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Nunbhakdi-Craig</surname><given-names>V</given-names></string-name>, <string-name><surname>Lee</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies</article-title>. <source>J Biol Chem</source>. <year>1999</year>;<volume>274</volume>:<fpage>25490</fpage>&#x2013;<lpage>25498</lpage>.</mixed-citation>
      </ref>
      <ref id="awac326-B29">
        <label>29</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Peng</surname>
<given-names>X</given-names>
</string-name>, <string-name><surname>Tehranian</surname><given-names>R</given-names></string-name>, <string-name><surname>Dietrich</surname><given-names>P</given-names></string-name>, <string-name><surname>Stefanis</surname><given-names>L</given-names></string-name>, <string-name><surname>Perez</surname><given-names>RG</given-names></string-name></person-group>. <article-title>Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells</article-title>. <source>J Cell Sci</source>. <year>2005</year>;<volume>118</volume>(<issue>15</issue>):<fpage>3523</fpage>&#x2013;<lpage>3530</lpage>.<pub-id pub-id-type="pmid">16030137</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B30">
        <label>30</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lou</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Montoya</surname><given-names>SE</given-names></string-name>, <string-name><surname>Alerte</surname><given-names>TN</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo</article-title>. <source>J Biol Chem</source>. <year>2010</year>;<volume>285</volume>:<fpage>17648</fpage>&#x2013;<lpage>17661</lpage>.<pub-id pub-id-type="pmid">20356833</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B31">
        <label>31</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Liu</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Zhou</surname><given-names>XW</given-names></string-name>, <string-name><surname>Tanila</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology</article-title>. <source>J Cell Mol Med</source>. <year>2008</year>;<volume>12</volume>:<fpage>241</fpage>&#x2013;<lpage>257</lpage>.<pub-id pub-id-type="pmid">18208556</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B32">
        <label>32</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gnanaprakash</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Staniszewski</surname><given-names>A</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Leucine carboxyl methyltransferase 1 overexpression protects against cognitive and electrophysiological impairments in Tg2576 APP transgenic mice</article-title>. <source>J Alzheimers Dis</source>. <year>2021</year>;<volume>79</volume>:<fpage>1813</fpage>&#x2013;<lpage>1829</lpage>.<pub-id pub-id-type="pmid">33459709</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B33">
        <label>33</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Lou</surname><given-names>SS</given-names></string-name>, <string-name><surname>Wang</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>UBE3A-mediated PTPA ubiquitination and degradation regulate PP2A activity and dendritic spine morphology</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2019</year>;<volume>116</volume>:<fpage>12500</fpage>&#x2013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">31160454</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B34">
        <label>34</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Abecasis</surname>
<given-names>GR</given-names>
</string-name>, <string-name><surname>Cherny</surname><given-names>SS</given-names></string-name>, <string-name><surname>Cookson</surname><given-names>WO</given-names></string-name>, <string-name><surname>Cardon</surname><given-names>LR</given-names></string-name></person-group>. <article-title>Merlin&#x2014;rapid analysis of dense genetic maps using sparse gene flow trees</article-title>. <source>Nat Genet</source>. <year>2002</year>;<volume>30</volume>:<fpage>97</fpage>&#x2013;<lpage>101</lpage>.<pub-id pub-id-type="pmid">11731797</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B35">
        <label>35</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>McKenna</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Hanna</surname><given-names>M</given-names></string-name>, <string-name><surname>Banks</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data</article-title>. <source>Genome Res</source>. <year>2010</year>;<volume>20</volume>:<fpage>1297</fpage>&#x2013;<lpage>1303</lpage>.<pub-id pub-id-type="pmid">20644199</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B36">
        <label>36</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Li</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Durbin</surname><given-names>R</given-names></string-name></person-group>. <article-title>Fast and accurate short read alignment with Burrows-Wheeler transform</article-title>. <source>Bioinformatics</source>. <year>2009</year>;<volume>25</volume>:<fpage>1754</fpage>&#x2013;<lpage>1760</lpage>.<pub-id pub-id-type="pmid">19451168</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B37">
        <label>37</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jian</surname>
<given-names>X</given-names>
</string-name>, <string-name><surname>Boerwinkle</surname><given-names>E</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X</given-names></string-name></person-group>. <article-title>In silico prediction of splice-altering single nucleotide variants in the human genome</article-title>. <source>Nucleic Acids Res</source>. <year>2014</year>;<volume>42</volume>:<fpage>13534</fpage>&#x2013;<lpage>13544</lpage>.<pub-id pub-id-type="pmid">25416802</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B38">
        <label>38</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jaganathan</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Kyriazopoulou Panagiotopoulou</surname><given-names>S</given-names></string-name>, <string-name><surname>McRae</surname><given-names>JF</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Predicting splicing from primary sequence with deep learning</article-title>. <source>Cell</source>. <year>2019</year>;<volume>176</volume>:<fpage>535</fpage>&#x2013;<lpage>48.e24</lpage>.<pub-id pub-id-type="pmid">30661751</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B39">
        <label>39</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Danis</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Jacobsen</surname><given-names>JOB</given-names></string-name>, <string-name><surname>Carmody</surname><given-names>LC</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Interpretable prioritization of splice variants in diagnostic next-generation sequencing</article-title>. <source>Am J Hum Genet</source>. <year>2021</year>;<volume>108</volume>:<fpage>2205</fpage>.<pub-id pub-id-type="pmid">34739835</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B40">
        <label>40</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>McLaren</surname>
<given-names>W</given-names>
</string-name>, <string-name><surname>Gil</surname><given-names>L</given-names></string-name>, <string-name><surname>Hunt</surname><given-names>SE</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>The ensembl variant effect predictor</article-title>. <source>Genome Biol</source>. <year>2016</year>;<volume>17</volume>:<fpage>122</fpage>.<pub-id pub-id-type="pmid">27268795</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B41">
        <label>41</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wang</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Li</surname><given-names>M</given-names></string-name>, <string-name><surname>Hadley</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data</article-title>. <source>Genome Res</source>. <year>2007</year>;<volume>17</volume>:<fpage>1665</fpage>&#x2013;<lpage>1674</lpage>.</mixed-citation>
      </ref>
      <ref id="awac326-B42">
        <label>42</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Colella</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Yau</surname><given-names>C</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>JM</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>QuantiSNP: an objective Bayes hidden-Markov model to detect and accurately map copy number variation using SNP genotyping data</article-title>. <source>Nucleic Acids Res</source>. <year>2007</year>;<volume>35</volume>:<fpage>2013</fpage>&#x2013;<lpage>2025</lpage>.</mixed-citation>
      </ref>
      <ref id="awac326-B43">
        <label>43</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Desvignes</surname>
<given-names>JP</given-names>
</string-name>, <string-name><surname>Bartoli</surname><given-names>M</given-names></string-name>, <string-name><surname>Delague</surname><given-names>V</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>VarAFT: a variant annotation and filtration system for human next generation sequencing data</article-title>. <source>Nucleic Acids Res</source>. <year>2018</year>;<volume>46</volume>(<issue>W1</issue>):<fpage>W545</fpage>&#x2013;<lpage>WW53</lpage>.</mixed-citation>
      </ref>
      <ref id="awac326-B44">
        <label>44</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Karczewski</surname>
<given-names>KJ</given-names>
</string-name>, <string-name><surname>Francioli</surname><given-names>LC</given-names></string-name>, <string-name><surname>Tiao</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>The mutational constraint spectrum quantified from variation in 141,456 humans</article-title>. <source>Nature</source>. <year>2020</year>;<volume>581</volume>:<fpage>434</fpage>&#x2013;<lpage>443</lpage>.</mixed-citation>
      </ref>
      <ref id="awac326-B45">
        <label>45</label>
        <mixed-citation publication-type="other">
<date-in-citation content-type="access">RCSB PDB - 2G62: Crystal structure of PTPA. Accessed 1 October 2021</date-in-citation>. <ext-link xlink:href="https://www.rcsb.org/structure/2g62" ext-link-type="uri">https://www.rcsb.org/structure/2g62</ext-link></mixed-citation>
      </ref>
      <ref id="awac326-B46">
        <label>46</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chao</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Xing</surname><given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Structure and mechanism of the phosphotyrosyl phosphatase activator</article-title>. <source>Mol Cell</source>. <year>2006</year>;<volume>23</volume>:<fpage>535</fpage>&#x2013;<lpage>546</lpage>.<pub-id pub-id-type="pmid">16916641</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B47">
        <label>47</label>
        <mixed-citation publication-type="other">
<date-in-citation content-type="access">CCDS report for consensus CDS. Report for CCDS6920.1. Accessed 15 May 2021</date-in-citation>. <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/CCDS/CcdsBrowse.cgi?REQUEST=CCDS&amp;DATA=CCDS6920" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/CCDS/CcdsBrowse.cgi?REQUEST=CCDS&amp;DATA=CCDS6920</ext-link></mixed-citation>
      </ref>
      <ref id="awac326-B48">
        <label>48</label>
        <mixed-citation publication-type="other">
<date-in-citation content-type="access">Primer 3. Accessed 1 May 2021</date-in-citation>. <ext-link xlink:href="https://bioinfo.ut.ee/primer3-0.4.0/" ext-link-type="uri">https://bioinfo.ut.ee/primer3-0.4.0/</ext-link></mixed-citation>
      </ref>
      <ref id="awac326-B49">
        <label>49</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Livak</surname>
<given-names>KJ</given-names>
</string-name>, <string-name><surname>Schmittgen</surname><given-names>TD</given-names></string-name></person-group>. <article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method</article-title>. <source>Methods</source>. <year>2001</year>;<volume>25</volume>:<fpage>402</fpage>&#x2013;<lpage>408</lpage>.<pub-id pub-id-type="pmid">11846609</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B50">
        <label>50</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Qiao</surname>
<given-names>H-H</given-names>
</string-name>, <string-name><surname>Wang</surname><given-names>F</given-names></string-name>, <string-name><surname>Xu</surname><given-names>R-G</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>An efficient and multiple target transgenic RNAi technique with low toxicity in Drosophila</article-title>. <source>Nat Commun</source>. <year>2018</year>;<volume>9</volume>:<fpage>4160</fpage>.<pub-id pub-id-type="pmid">30297884</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B51">
        <label>51</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hu</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Flockhart</surname><given-names>I</given-names></string-name>, <string-name><surname>Vinayagam</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>An integrative approach to ortholog prediction for disease-focused and other functional studies</article-title>. <source>BMC Bioinformatics</source>. <year>2011</year>;<volume>12</volume>:<fpage>357</fpage>.<pub-id pub-id-type="pmid">21880147</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B52">
        <label>52</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sang</surname>
<given-names>TK</given-names>
</string-name>, <string-name><surname>Chang</surname><given-names>HY</given-names></string-name>, <string-name><surname>Lawless</surname><given-names>GM</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>A Drosophila model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine</article-title>. <source>J Neurosci</source>. <year>2007</year>;<volume>27</volume>:<fpage>981</fpage>&#x2013;<lpage>992</lpage>.<pub-id pub-id-type="pmid">17267552</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B53">
        <label>53</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schneider</surname>
<given-names>CA</given-names>
</string-name>, <string-name><surname>Rasband</surname><given-names>WS</given-names></string-name>, <string-name><surname>Eliceiri</surname><given-names>KW</given-names></string-name></person-group>. <article-title>NIH Image to ImageJ: 25 years of image analysis</article-title>. <source>Nat Methods</source>. <year>2012</year>;<volume>9</volume>:<fpage>671</fpage>&#x2013;<lpage>675</lpage>.<pub-id pub-id-type="pmid">22930834</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B54">
        <label>54</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rentzsch</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Witten</surname><given-names>D</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>GM</given-names></string-name>, <string-name><surname>Shendure</surname><given-names>J</given-names></string-name>, <string-name><surname>Kircher</surname><given-names>M</given-names></string-name></person-group>. <article-title>CADD: predicting the deleteriousness of variants throughout the human genome</article-title>. <source>Nucleic Acids Res</source>. <year>2019</year>;<volume>47</volume>(<issue>D1</issue>):<fpage>D886</fpage>&#x2013;<lpage>D894</lpage>.<pub-id pub-id-type="pmid">30371827</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B55">
        <label>55</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Davydov</surname>
<given-names>EV</given-names>
</string-name>, <string-name><surname>Goode</surname><given-names>DL</given-names></string-name>, <string-name><surname>Sirota</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Identifying a high fraction of the human genome to be under selective constraint using GERP++</article-title>. <source>PLoS Comput Biol</source>. <year>2010</year>;<volume>6(12)</volume>:<fpage>e1001025</fpage>.<pub-id pub-id-type="pmid">21152010</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B56">
        <label>56</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Havrilla</surname>
<given-names>JM</given-names>
</string-name>, <string-name><surname>Pedersen</surname><given-names>BS</given-names></string-name>, <string-name><surname>Layer</surname><given-names>RM</given-names></string-name>, <string-name><surname>Quinlan</surname><given-names>AR</given-names></string-name></person-group>. <article-title>A map of constrained coding regions in the human genome</article-title>. <source>Nat Genet</source>. <year>2019</year>;<volume>51</volume>:<fpage>88</fpage>&#x2013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">30531870</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B57">
        <label>57</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kim</surname>
<given-names>JJ</given-names>
</string-name>, <string-name><surname>Makarious</surname><given-names>MB</given-names></string-name>, <string-name><surname>Bandres-Ciga</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>The Parkinson's disease DNA variant browser</article-title>. <source>Mov Disord</source>. <year>2021</year>;<volume>36</volume>:<fpage>1250</fpage>&#x2013;<lpage>1258</lpage>.<pub-id pub-id-type="pmid">33497488</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B58">
        <label>58</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Viechtbauer</surname>
<given-names>W</given-names>
</string-name>
</person-group>. <article-title>Conducting meta-analyses in <italic toggle="yes">R</italic> with the metafor package</article-title>. <source>J Stat Softw.</source><year>2010</year>;<volume>36</volume>:<fpage>1</fpage>&#x2013;<lpage>48</lpage>.</mixed-citation>
      </ref>
      <ref id="awac326-B59">
        <label>59</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Silverstein</surname>
<given-names>AM</given-names>
</string-name>, <string-name><surname>Barrow</surname><given-names>CA</given-names></string-name>, <string-name><surname>Davis</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Mumby</surname><given-names>MC</given-names></string-name></person-group>. <article-title>Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2002</year>;<volume>99</volume>:<fpage>4221</fpage>&#x2013;<lpage>4226</lpage>.<pub-id pub-id-type="pmid">11904383</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B60">
        <label>60</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Li</surname>
<given-names>X</given-names>
</string-name>, <string-name><surname>Scuderi</surname><given-names>A</given-names></string-name>, <string-name><surname>Letsou</surname><given-names>A</given-names></string-name>, <string-name><surname>Virshup</surname><given-names>DM</given-names></string-name></person-group>. <article-title>B56-associated protein phosphatase 2A is required for survival and protects from apoptosis in Drosophila melanogaster</article-title>. <source>Mol Cell Biol</source>. <year>2002</year>;<volume>22</volume>:<fpage>3674</fpage>&#x2013;<lpage>3684</lpage>.<pub-id pub-id-type="pmid">11997504</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B61">
        <label>61</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Baharians</surname>
<given-names>Z</given-names>
</string-name>, <string-name><surname>Sch&#xF6;nthal</surname><given-names>AH</given-names></string-name></person-group>. <article-title>Autoregulation of protein phosphatase type 2A expression</article-title>. <source>J Biol Chem</source>. <year>1998</year>;<volume>273</volume>:<fpage>19019</fpage>&#x2013;<lpage>19024</lpage>.<pub-id pub-id-type="pmid">9668082</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B62">
        <label>62</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Janssens</surname>
<given-names>V</given-names>
</string-name>, <string-name><surname>Goris</surname><given-names>J</given-names></string-name></person-group>. <article-title>Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling</article-title>. <source>Biochem J</source>. <year>2001</year>;<volume>353</volume>(<issue>3</issue>):<fpage>417</fpage>&#x2013;<lpage>439</lpage>.<pub-id pub-id-type="pmid">11171037</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B63">
        <label>63</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>McCright</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Rivers</surname><given-names>AM</given-names></string-name>, <string-name><surname>Audlin</surname><given-names>S</given-names></string-name>, <string-name><surname>Virshup</surname><given-names>DM</given-names></string-name></person-group>. <article-title>The B56 family of protein phosphatase 2A (PP2A) regulatory subunits encodes differentiation-induced phosphoproteins that target PP2A to both nucleus and cytoplasm</article-title>. <source>J Biol Chem</source>. <year>1996</year>;<volume>271</volume>:<fpage>22081</fpage>&#x2013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">8703017</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B64">
        <label>64</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nalls</surname>
<given-names>MA</given-names>
</string-name>, <string-name><surname>Blauwendraat</surname><given-names>C</given-names></string-name>, <string-name><surname>Vallerga</surname><given-names>CL</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies</article-title>. <source>Lancet Neurol</source>. <year>2019</year>;<volume>18</volume>:<fpage>1091</fpage>&#x2013;<lpage>1102</lpage>.<pub-id pub-id-type="pmid">31701892</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B65">
        <label>65</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>K&#xF6;ro&#x11F;lu</surname>
<given-names>&#xC7;</given-names>
</string-name>, <string-name><surname>Baysal</surname><given-names>L</given-names></string-name>, <string-name><surname>Cetinkaya</surname><given-names>M</given-names></string-name>, <string-name><surname>Karasoy</surname><given-names>H</given-names></string-name>, <string-name><surname>Tolun</surname><given-names>A</given-names></string-name></person-group>. <article-title>DNAJC6 Is responsible for juvenile parkinsonism with phenotypic variability</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2013</year>;<volume>19</volume>:<fpage>320</fpage>&#x2013;<lpage>324</lpage>.<pub-id pub-id-type="pmid">23211418</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B66">
        <label>66</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lesage</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Bras</surname><given-names>J</given-names></string-name>, <string-name><surname>Cormier-Dequaire</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Loss-of-function mutations in <italic toggle="yes">RAB39B</italic> are associated with typical early-onset Parkinson disease</article-title>. <source>Neurol Genet</source>. <year>2015</year>;<volume>1</volume>:<fpage>e9</fpage>.<pub-id pub-id-type="pmid">27066548</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B67">
        <label>67</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wilson</surname>
<given-names>GR</given-names>
</string-name>, <string-name><surname>Sim</surname><given-names>JC</given-names></string-name>, <string-name><surname>McLean</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with &#x3B1;-synuclein pathology</article-title>. <source>Am J Hum Genet</source>. <year>2014</year>;<volume>95</volume>:<fpage>729</fpage>&#x2013;<lpage>735</lpage>.<pub-id pub-id-type="pmid">25434005</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B68">
        <label>68</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wirth</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Mariani</surname><given-names>LL</given-names></string-name>, <string-name><surname>Bergant</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Loss-of-function mutations in <italic toggle="yes">NR4A2</italic> cause dopa-responsive dystonia parkinsonism</article-title>. <source>Mov Disord</source>. <year>2020</year>;<volume>35</volume>:<fpage>880</fpage>&#x2013;<lpage>885</lpage>.<pub-id pub-id-type="pmid">31922365</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B69">
        <label>69</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Haack</surname>
<given-names>TB</given-names>
</string-name>, <string-name><surname>Hogarth</surname><given-names>P</given-names></string-name>, <string-name><surname>Kruer</surname><given-names>MC</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA</article-title>. <source>Am J Hum Genet</source>. <year>2012</year>;<volume>91</volume>:<fpage>1144</fpage>&#x2013;<lpage>1149</lpage>.<pub-id pub-id-type="pmid">23176820</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B70">
        <label>70</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Manti</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Panteghini</surname><given-names>C</given-names></string-name>, <string-name><surname>Garavaglia</surname><given-names>B</given-names></string-name>, <string-name><surname>Leuzzi</surname><given-names>V</given-names></string-name></person-group>. <article-title>Neurodevelopmental disorder and late-onset degenerative parkinsonism in a patient with a <italic toggle="yes">WDR45</italic> defect</article-title>. <source>Mov Disord Clin Pract</source>. <year>2022</year>;<volume>9</volume>:<fpage>110</fpage>&#x2013;<lpage>112</lpage>.<pub-id pub-id-type="pmid">35005074</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B71">
        <label>71</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Khodadadi</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Azcona</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Aghamollaii</surname><given-names>V</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>
<italic toggle="yes">PTRHD1</italic> (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism</article-title>. <source>Mov Disord</source>. <year>2017</year>;<volume>32</volume>:<fpage>287</fpage>&#x2013;<lpage>291</lpage>.<pub-id pub-id-type="pmid">27753167</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B72">
        <label>72</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kuipers</surname>
<given-names>DJS</given-names>
</string-name>, <string-name><surname>Carr</surname><given-names>J</given-names></string-name>, <string-name><surname>Bardien</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>
<italic toggle="yes">PTRHD1</italic> Loss-of-function mutation in an African family with juvenile-onset Parkinsonism and intellectual disability</article-title>. <source>Mov Disord</source>. <year>2018</year>;<volume>33</volume>:<fpage>1814</fpage>&#x2013;<lpage>1819</lpage>.<pub-id pub-id-type="pmid">30398675</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B73">
        <label>73</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mignogna</surname>
<given-names>ML</given-names>
</string-name>, <string-name><surname>Giannandrea</surname><given-names>M</given-names></string-name>, <string-name><surname>Gurgone</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>The intellectual disability protein RAB39B selectively regulates GluA2 trafficking to determine synaptic AMPAR composition</article-title>. <source>Nat Commun</source>. <year>2015</year>;<volume>6</volume>:<fpage>6504</fpage>.<pub-id pub-id-type="pmid">25784538</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B74">
        <label>74</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Pishvaee</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Costaguta</surname><given-names>G</given-names></string-name>, <string-name><surname>Yeung</surname><given-names>BG</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>A yeast DNA J protein required for uncoating of clathrin-coated vesicles in vivo</article-title>. <source>Nat Cell Biol</source>. <year>2000</year>;<volume>2</volume>:<fpage>958</fpage>&#x2013;<lpage>963</lpage>.<pub-id pub-id-type="pmid">11146663</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B75">
        <label>75</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lee</surname>
<given-names>DW</given-names>
</string-name>, <string-name><surname>Zhao</surname><given-names>X</given-names></string-name>, <string-name><surname>Yim</surname><given-names>YI</given-names></string-name>, <string-name><surname>Eisenberg</surname><given-names>E</given-names></string-name>, <string-name><surname>Greene</surname><given-names>LE</given-names></string-name></person-group>. <article-title>Essential role of cyclin-G-associated kinase (Auxilin-2) in developing and mature mice</article-title>. <source>Mol Biol Cell</source>. <year>2008</year>;<volume>19</volume>:<fpage>2766</fpage>&#x2013;<lpage>2776</lpage>.<pub-id pub-id-type="pmid">18434600</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B76">
        <label>76</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Grimmel</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Backhaus</surname><given-names>C</given-names></string-name>, <string-name><surname>Proikas-Cezanne</surname><given-names>T</given-names></string-name></person-group>. <article-title>WIPI-mediated autophagy and longevity</article-title>. <source>Cells</source>. <year>2015</year>;<volume>4</volume>:<fpage>202</fpage>&#x2013;<lpage>217</lpage>.<pub-id pub-id-type="pmid">26010754</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B77">
        <label>77</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hedya</surname>
<given-names>SA</given-names>
</string-name>, <string-name><surname>Safar</surname><given-names>MM</given-names></string-name>, <string-name><surname>Bahgat</surname><given-names>AK</given-names></string-name></person-group>. <article-title>Hydroxychloroquine antiparkinsonian potential: Nurr1 modulation versus autophagy inhibition</article-title>. <source>Behav Brain Res</source>. <year>2019</year>;<volume>365</volume>:<fpage>82</fpage>&#x2013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">30797853</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B78">
        <label>78</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Niu</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Zheng</surname><given-names>N</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>RAB39B deficiency impairs learning and memory partially through compromising autophagy</article-title>. <source>Front Cell Dev Biol</source>. <year>2020</year>;<volume>8</volume>:<fpage>598622</fpage>.<pub-id pub-id-type="pmid">33364235</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B79">
        <label>79</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ishii</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Funakoshi</surname><given-names>M</given-names></string-name>, <string-name><surname>Kobayashi</surname><given-names>H</given-names></string-name></person-group>. <article-title>Yeast Pth2 is a UBL domain-binding protein that participates in the ubiquitin&#x2013;proteasome pathway</article-title>. <source>EMBO J</source>. <year>2006</year>;<volume>25</volume>:<fpage>5492</fpage>&#x2013;<lpage>5503</lpage>.<pub-id pub-id-type="pmid">17082762</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B80">
        <label>80</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lewis Patrick</surname>
<given-names>A</given-names>
</string-name>
</person-group>. <article-title>Vesicular dysfunction and pathways to neurodegeneration</article-title>. <source>Essays Biochem</source>. <year>2021</year>;<volume>65</volume>:<fpage>941</fpage>&#x2013;<lpage>948</lpage>.</mixed-citation>
      </ref>
      <ref id="awac326-B81">
        <label>81</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Merino-Gal&#xE1;n</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Jimenez-Urbieta</surname><given-names>H</given-names></string-name>, <string-name><surname>Zamarbide</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Striatal synaptic bioenergetic and autophagic decline in premotor experimental parkinsonism</article-title>. <source>Brain</source>. <year>2022</year>;<volume>145(6)</volume>:<fpage>2092</fpage>&#x2013;<lpage>2107</lpage>.<pub-id pub-id-type="pmid">35245368</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B82">
        <label>82</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zheng</surname>
<given-names>Q</given-names>
</string-name>, <string-name><surname>Huang</surname><given-names>T</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Dysregulation of ubiquitin-proteasome system in neurodegenerative diseases</article-title>. <source>Front Aging Neurosci</source>. <year>2016</year>;<volume>8</volume>:<fpage>303</fpage>.<pub-id pub-id-type="pmid">28018215</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B83">
        <label>83</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Van Bergen</surname>
<given-names>NJ</given-names>
</string-name>, <string-name><surname>Guo</surname><given-names>Y</given-names></string-name>, <string-name><surname>Al-Deri</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Deficiencies in vesicular transport mediated by TRAPPC4 are associated with severe syndromic intellectual disability</article-title>. <source>Brain</source>. <year>2020</year>;<volume>143</volume>:<fpage>112</fpage>&#x2013;<lpage>130</lpage>.<pub-id pub-id-type="pmid">31794024</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B84">
        <label>84</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ji</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Zhao</surname><given-names>YG</given-names></string-name></person-group>. <article-title>The BPAN and intellectual disability disease proteins WDR45 and WDR45B modulate autophagosome-lysosome fusion</article-title>. <source>Autophagy</source>. <year>2021</year>;<volume>17</volume>:<fpage>1783</fpage>&#x2013;<lpage>1784</lpage>.<pub-id pub-id-type="pmid">34105435</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B85">
        <label>85</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cheon</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Dean</surname><given-names>M</given-names></string-name>, <string-name><surname>Chahrour</surname><given-names>M</given-names></string-name></person-group>. <article-title>The ubiquitin proteasome pathway in neuropsychiatric disorders</article-title>. <source>Neurobiol Learn Mem</source>. <year>2019</year>;<volume>165</volume>:<fpage>106791</fpage>.<pub-id pub-id-type="pmid">29398581</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B86">
        <label>86</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<collab>Deciphering Developmental Disorders Study</collab>
</person-group>. <article-title>Large-scale discovery of novel genetic causes of developmental disorders</article-title>. <source>Nature</source>. <year>2015</year>;<volume>519</volume>:<fpage>223</fpage>&#x2013;<lpage>228</lpage>.<pub-id pub-id-type="pmid">25533962</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B87">
        <label>87</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lenaerts</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Reynhout</surname><given-names>S</given-names></string-name>, <string-name><surname>Verbinnen</surname><given-names>I</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>The broad phenotypic spectrum of PPP2R1A-related neurodevelopmental disorders correlates with the degree of biochemical dysfunction</article-title>. <source>Genet Med</source>. <year>2021</year>;<volume>23</volume>:<fpage>352</fpage>&#x2013;<lpage>362</lpage>.<pub-id pub-id-type="pmid">33106617</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B88">
        <label>88</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Houge</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Haesen</surname><given-names>D</given-names></string-name>, <string-name><surname>Vissers</surname><given-names>LE</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>B56&#x3B4;-related protein phosphatase 2A dysfunction identified in patients with intellectual disability</article-title>. <source>J Clin Invest</source>. <year>2015</year>;<volume>125</volume>:<fpage>3051</fpage>&#x2013;<lpage>3062</lpage>.<pub-id pub-id-type="pmid">26168268</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B89">
        <label>89</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Reynhout</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Jansen</surname><given-names>S</given-names></string-name>, <string-name><surname>Haesen</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>De Novo mutations affecting the catalytic C&#x3B1; subunit of PP2A, PPP2CA, cause syndromic intellectual disability resembling other PP2A-related neurodevelopmental disorders</article-title>. <source>Am J Hum Genet</source>. <year>2019</year>;<volume>104</volume>:<fpage>139</fpage>&#x2013;<lpage>156</lpage>.<pub-id pub-id-type="pmid">30595372</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B90">
        <label>90</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Graham JM</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Wheeler</surname><given-names>P</given-names></string-name>, <string-name><surname>Tackels-Horne</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>A new X-linked syndrome with agenesis of the corpus callosum, mental retardation, coloboma, micrognathia, and a mutation in the alpha 4 gene at Xq13</article-title>. <source>Am J Med Genet A</source>. <year>2003</year>;<volume>123A</volume>:<fpage>37</fpage>&#x2013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">14556245</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B91">
        <label>91</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Piton</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Redin</surname><given-names>C</given-names></string-name>, <string-name><surname>Mandel</surname><given-names>JL</given-names></string-name></person-group>. <article-title>XLID-causing mutations and associated genes challenged in light of data from large-scale human exome sequencing</article-title>. <source>Am J Hum Genet</source>. <year>2013</year>;<volume>93</volume>:<fpage>368</fpage>&#x2013;<lpage>383</lpage>.<pub-id pub-id-type="pmid">23871722</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B92">
        <label>92</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Backx</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Vermeesch</surname><given-names>J</given-names></string-name>, <string-name><surname>Pijkels</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>PPP2R2C, A gene disrupted in autosomal dominant intellectual disability</article-title>. <source>Eur J Med Genet</source>. <year>2010</year>;<volume>53</volume>:<fpage>239</fpage>&#x2013;<lpage>243</lpage>.<pub-id pub-id-type="pmid">20601260</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B93">
        <label>93</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Loveday</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Tatton-Brown</surname><given-names>K</given-names></string-name>, <string-name><surname>Clarke</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Mutations in the PP2A regulatory subunit B family genes <italic toggle="yes">PPP2R5B</italic>, <italic toggle="yes">PPP2R5C</italic> and <italic toggle="yes">PPP2R5D</italic> cause human overgrowth</article-title>. <source>Hum Mol Genet</source>. <year>2015</year>;<volume>24</volume>:<fpage>4775</fpage>&#x2013;<lpage>4779</lpage>.<pub-id pub-id-type="pmid">25972378</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B94">
        <label>94</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mohrmann</surname>
<given-names>I</given-names>
</string-name>, <string-name><surname>Gillessen-Kaesbach</surname><given-names>G</given-names></string-name>, <string-name><surname>Siebert</surname><given-names>R</given-names></string-name>, <string-name><surname>Caliebe</surname><given-names>A</given-names></string-name>, <string-name><surname>Hellenbroich</surname><given-names>Y</given-names></string-name></person-group>. <article-title>A de novo 0.57 Mb microdeletion in chromosome 11q13.1 in a patient with speech problems, autistic traits, dysmorphic features and multiple endocrine neoplasia type 1</article-title>. <source>Eur J Med Genet</source>. <year>2011</year>;<volume>54</volume>:<fpage>e461</fpage>&#x2013;<lpage>e464</lpage>.<pub-id pub-id-type="pmid">21600320</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B95">
        <label>95</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Boyle</surname>
<given-names>MI</given-names>
</string-name>, <string-name><surname>Jespersgaard</surname><given-names>C</given-names></string-name>, <string-name><surname>Nazaryan</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Deletion of 11q12.3-11q13.1 in a patient with intellectual disability and childhood facial features resembling Cornelia de Lange syndrome</article-title>. <source>Gene</source>. <year>2015</year>;<volume>572</volume>:<fpage>130</fpage>&#x2013;<lpage>134</lpage>.<pub-id pub-id-type="pmid">26164757</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B96">
        <label>96</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hamdan</surname>
<given-names>FF</given-names>
</string-name>, <string-name><surname>Srour</surname><given-names>M</given-names></string-name>, <string-name><surname>Capo-Chichi</surname><given-names>JM</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>De novo mutations in moderate or severe intellectual disability</article-title>. <source>PLoS Genet</source>. <year>2014</year>;<volume>10</volume>:<comment>e1004772</comment>.</mixed-citation>
      </ref>
      <ref id="awac326-B97">
        <label>97</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shang</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Henderson</surname><given-names>LB</given-names></string-name>, <string-name><surname>Cho</surname><given-names>MT</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>De novo missense variants in PPP2R5D are associated with intellectual disability, macrocephaly, hypotonia, and autism</article-title>. <source>Neurogenetics</source>. <year>2016</year>;<volume>17</volume>:<fpage>43</fpage>&#x2013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">26576547</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B98">
        <label>98</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kim</surname>
<given-names>CY</given-names>
</string-name>, <string-name><surname>Wirth</surname><given-names>T</given-names></string-name>, <string-name><surname>Hubsch</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Early-onset parkinsonism is a manifestation of the <italic toggle="yes">PPP2R5D</italic> p.E200K mutation</article-title>. <source>Ann Neurol</source>. <year>2020</year>;<volume>88</volume>:<fpage>1028</fpage>&#x2013;<lpage>1033</lpage>.<pub-id pub-id-type="pmid">32743835</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B99">
        <label>99</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Walker</surname>
<given-names>IM</given-names>
</string-name>, <string-name><surname>Riboldi</surname><given-names>GM</given-names></string-name>, <string-name><surname>Drummond</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>
<italic toggle="yes">PPP2R5D</italic> genetic mutations and early-onset parkinsonism</article-title>. <source>Ann Neurol</source>. <year>2021</year>;<volume>89</volume>:<fpage>194</fpage>&#x2013;<lpage>195</lpage>.<pub-id pub-id-type="pmid">33098144</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B100">
        <label>100</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hetzelt</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Kerling</surname><given-names>F</given-names></string-name>, <string-name><surname>Kraus</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Early-onset parkinsonism in PPP2R5D-related neurodevelopmental disorder</article-title>. <source>Eur J Med Genet</source>. <year>2021</year>;<volume>64</volume>:<fpage>104123</fpage>.<pub-id pub-id-type="pmid">33338668</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B101">
        <label>101</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ning</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Li</surname><given-names>K</given-names></string-name>, <string-name><surname>Ren</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Rare missense variants in the PPP2R5D gene associated with Parkinson's disease in the Han Chinese population</article-title>. <source>Neurosci Lett</source>. <year>2022</year>;<volume>776</volume>:<fpage>136564</fpage>.<pub-id pub-id-type="pmid">35257824</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B102">
        <label>102</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Manning</surname>
<given-names>KS</given-names>
</string-name>, <string-name><surname>Cooper</surname><given-names>TA</given-names></string-name></person-group>. <article-title>The roles of RNA processing in translating genotype to phenotype</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2017</year>;<volume>18</volume>:<fpage>102</fpage>&#x2013;<lpage>114</lpage>.<pub-id pub-id-type="pmid">27847391</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B103">
        <label>103</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ghanbari</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Franco</surname><given-names>OH</given-names></string-name>, <string-name><surname>de Looper</surname><given-names>HW</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Genetic variations in MicroRNA-binding sites affect MicroRNA-mediated regulation of several genes associated with cardio-metabolic phenotypes</article-title>. <source>Circ Cardiovasc Genet</source>. <year>2015</year>;<volume>8</volume>:<fpage>473</fpage>&#x2013;<lpage>486</lpage>.<pub-id pub-id-type="pmid">25814643</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B104">
        <label>104</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wang</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>van der Walt</surname><given-names>JM</given-names></string-name>, <string-name><surname>Mayhew</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein</article-title>. <source>Am J Hum Genet</source>. <year>2008</year>;<volume>82</volume>:<fpage>283</fpage>&#x2013;<lpage>289</lpage>.</mixed-citation>
      </ref>
      <ref id="awac326-B105">
        <label>105</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wan</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Qu</surname><given-names>K</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>QC</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Landscape and variation of RNA secondary structure across the human transcriptome</article-title>. <source>Nature</source>. <year>2014</year>;<volume>505</volume>:<fpage>706</fpage>&#x2013;<lpage>709</lpage>.</mixed-citation>
      </ref>
      <ref id="awac326-B106">
        <label>106</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Duan</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Wainwright</surname><given-names>MS</given-names></string-name>, <string-name><surname>Comeron</surname><given-names>JM</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor</article-title>. <source>Hum Mol Genet</source>. <year>2003</year>;<volume>12</volume>:<fpage>205</fpage>&#x2013;<lpage>216</lpage>.</mixed-citation>
      </ref>
      <ref id="awac326-B107">
        <label>107</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sents</surname>
<given-names>W</given-names>
</string-name>, <string-name><surname>Meeusen</surname><given-names>B</given-names></string-name>, <string-name><surname>Kalev</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>PP2A inactivation mediated by <italic toggle="yes">PPP2R4</italic> haploinsufficiency promotes cancer development</article-title>. <source>Cancer Res</source>. <year>2017</year>;<volume>77</volume>:<fpage>6825</fpage>&#x2013;<lpage>6837</lpage>.<pub-id pub-id-type="pmid">29046336</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B108">
        <label>108</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cayla</surname>
<given-names>X</given-names>
</string-name>, <string-name><surname>Goris</surname><given-names>J</given-names></string-name>, <string-name><surname>Hermann</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Isolation and characterization of a tyrosyl phosphatase activator from rabbit skeletal muscle and Xenopus laevis oocytes</article-title>. <source>Biochemistry</source>. <year>1990</year>;<volume>29</volume>:<fpage>658</fpage>&#x2013;<lpage>667</lpage>.<pub-id pub-id-type="pmid">2159785</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B109">
        <label>109</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Xiong</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Yu</surname><given-names>J</given-names></string-name></person-group>. <article-title>Modeling Parkinson's disease in Drosophila: what have we learned for dominant traits?</article-title><source>Front Neurol</source>. <year>2018</year>;<volume>9</volume>:<fpage>228</fpage>.<pub-id pub-id-type="pmid">29686647</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B110">
        <label>110</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Vanhauwaert</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Verstreken</surname><given-names>P</given-names></string-name></person-group>. <article-title>Flies with Parkinson's disease</article-title>. <source>Exp Neurol</source>. <year>2015</year>;<volume>274</volume>(<issue>Pt A</issue>):<fpage>42</fpage>&#x2013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">25708988</pub-id></mixed-citation>
      </ref>
      <ref id="awac326-B111">
        <label>111</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Feany</surname>
<given-names>MB</given-names>
</string-name>, <string-name><surname>Bender</surname><given-names>WW</given-names></string-name></person-group>. <article-title>A drosophila model of Parkinson's disease</article-title>. <source>Nature</source>. <year>2000</year>;<volume>404</volume>:<fpage>394</fpage>&#x2013;<lpage>398</lpage>.<pub-id pub-id-type="pmid">10746727</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>